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Abstract
A TOP-DOWN PROTEOMIC APPROACH FOR THE DISCOVERY OF
NOVEL SERUM BIOMARKERS OF PREGNANCY-RELATED DISEASE
Karen Merrell
Department of Chemistry and Biochemistry
Doctor of Philosophy

The serum fraction of blood is an ideal material in which to search for novel
biomarkers for disease. It is easily obtained through relatively non-invasive means,
routinely collected, and a rich treasure-trove of information about the health of an
individual. Cells react to signal molecules, take up nutrients, and release waste products,
fragments that are the result of proteolysis, and other molecules out into the bloodstream.
If these components are unique to the cells in question, that part of the complex mixture
that is the blood stream can potentially characterize the health of the tissue or organ those
cells are a part of.
Serum is dense with proteins that span over ten orders of magnitude in size and
abundance. The top 22 most abundant proteins in serum account for 99% of the total
protein. These abundant proteins are well-characterized and not useful in a search for
novel biomarkers for disease. Removal of these large proteins is accomplished using an
organic-solvent precipitation step. Analyzing the resultant mixture of low-molecularweight serum peptides using cLC-MS produces large, data-rich, and very complex data
files. We have developed a manual analysis method we have developed that is capable of
performing all of the processing steps necessary to identify novel biomarkers for disease

as well as a method for the sequencing of low-abundance, highly charged peptide species
without additional sample preparation.
These methods are applied to two serum sample sets collected to investigate two
pregnancy-related diseases: preterm birth, and preeclampsia. Three novel biomarkers of
preterm birth have been identified and a combination of these with 5 previously studied
markers can predict women who will have preterm birth with a sensitivity of 89.9% and a
specificity of 81.0%. Nineteen different molecular species have been identified that
predict women at risk for preeclampsia with a p-value of <0.05. Weighted combinations
of various groups of the 19 biomarkers can increase the sensitivity up to 96% and the
specificity up to 100%.
The use of cLC-MS in the search for novel serum biomarkers of pregnancyrelated disease allows for seamless integration from potential biomarker selection to
polypeptide sequence identification.
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Chapter 1 – Introduction
Protein Analysis
Prior to development of modern
instrumentation, different approaches to protein
analysis were used to investigate the molecular
properties of individual proteins. Some of the
properties commonly investigated were
biological activity, three dimensional structure,

Frederick Banting John Macleod

and amino acid sequence. Though somewhat

(http://nobelprize.org)

limited in their approaches, these studies provided valuable insight that advanced the
understanding of the importance of proteins. This is highlighted by some of the Nobel
prizes awarded for such ground breaking research in these areas. In
1923 the Nobel Prize in medicine was awarded to Frederick Banting
and John Macleod for the discovery of insulin. They isolated a
protein from pancreatic extracts, and demonstrated that the protein
retained biological activity. This protein kept a pancreatectomized
dog alive all summer because the extract lowered the level of sugar
in the blood. (Bliss 1982) Fred Sanger won a Nobel Prize in

Frederick Sanger
(http://nobelprize.org)

chemistry in 1958 for his work on the structure of proteins, especially that of insulin. In
that same year, John Kendrew and associates successfully determined the structure of
myoglobin by high-resolution X-ray crystallography. (Kendrew 1958) For their studies
of the structures of globular proteins, John Kendrew shared the 1962 Nobel Prize in
chemistry with Max Perutz. (nobelprize.org) Edman sequencing has been a standard
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method for protein amino acid sequence
identification since it was developed in 1970.
(Edman 1970) This method employs a stepwise
chemical degradation of a protein from its Nterminus. Because N-terminal modifications
block sequencing using this method, a method
employing enzymatic digestion step prior to

Max Perutz

John Kendrew

(http://nobelprize.org)

Edman sequencing of internal peptides was

developed. (Abersold 1987) Sequencing of enzymatically digested proteins, the online
publication of genomic databases, and the translated protein databases rendered from
them prepared the way for mass spectrometry (MS) based methods. (Patterson 2001)
Nearly all of the processes in living cells are accomplished by the effects of
proteins. The genome regulates the synthesis of all of these proteins. Many genome
projects have sequenced the structure and composition of entire genomes for many
different organisms. For example, there are ~8,000 genes in nematodes compared with
the ~22,000 genes in humans. The difference in organism complexity between
nematodes and humans cannot be explained by the genomes themselves: That of humans
is not that much larger than that of nematodes. The complexity of the human organism
compared to that of the nematodes must then be explained by the products of the genomic
“blueprint” rather than the blueprint itself. (Shaw 2008) Because the genomes of many
organisms have already been sequenced, it is often possible to predict protein sequences
that may result from the translation of specific gene sequences. There is no way to know
for sure which of these proteins are expressed in vivo. Analysis of the rough draft of the
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human genome showed that there were fewer protein-coding genes in the human genome
than there are proteins in the human proteome (~22,000 genes versus ~400,000 proteins).
(Yim 2006) This increase in protein diversity is thought to be a result of alternative
splicing, differential proteolysis, and posttranslational modification of proteins. The final
state of these proteins cannot be predicted through analysis of the genome. Thus, to
characterize the protein complement of cells and tissues of interest, a proteomics-based
approach is needed. (Zubrig 2008 Peptidomics)

Proteomics
The term proteome was coined in 1995 and defined as “the total protein content of
a genome.” (Kahn 1995, Wasinger 1995) This term was coined to make an analogy with
genomics, and is generally regarded as the “next step” in biological discovery. (Zubrig
2008 Peptidomics) Proteomics is the study of the proteome and involves the study of the
protein complement and their interactions in a cell, organ, tissue, or entire organism.
(Lundblad 2006) The genome is a constant entity whereas the proteome is constantly
changing and adapting as it interacts with the genome and the biochemical environment.
(Zubrig 2008 Biomarker) Because the protein complement of even a single cell is varied,
dynamic and complex, those researchers undertaking proteomic investigations have
developed many sophisticated techniques. These techniques allow researchers to
simplify and observe a representative segment or subset of the proteomes of biological
materials or specimens. Current methods of sample protein separation include onedimensional polyacrylamide gel electrophoresis (PAGE) to separate proteins by size,
two-dimensional PAGE (2D-GE) to separate proteins by isoelectric point as well as size,
and liquid chromatography to separate proteins by charge, size, or hydrophobicity.

3

PAGE was reported as early as 1970 (Laemmli 1970), and 2D-GE was reported five
years later. (O’Farrell 1975) The 2D gel separating and blotting techniques are still
widely and successfully used today despite limitations in reproducibility, sensitivity, and
lengthy analysis time.
There seems to be three general areas of inquiry for proteomics. The first is
analytical proteomics where the elucidation of the proteome is undertaken by analytical
means, including microarrays, mass spectrometry and various separation techniques. The
second is expression proteomics where some kind of stimulus is applied to a system and
the resulting change in protein expression and the underlying pathways are observed.
The third is biomarker identification where the protein complement from a healthy
organism is compared with that from one with a certain disease. Biochemical differences
in the proteome between cases and control can be utilized as biomarkers. (Lundblad
2006) Proteomics as an analytical tool has the potential to identify within a very complex
mixture of thousands of proteins, those individual proteins associated with change in
phenotype due to disease. (Anderson 1998) Subsequent studies can then be conducted to
see whether or not the observed correlation can provide clues as to the cause of or the
sequence of pathways leading to that particular disease.

Mass Spectrometry
With the advent of soft-ionization techniques like matrix-assisted laser desorption
ionization (MALDI) and electrospray ionization (ESI), mass spectrometry (MS) has been
useable for the analysis of larger biomolecules. These breakthroughs have enabled the
field of proteomics to expand beyond the mass and detection limits of 2D-GE. MS
instruments consist of at least three basic components; an ionization module, a mass
4

analyzer, and a detector. For ions to be able to move through the electromagnetic fields
of the mass analyzer they need to be charged. The ionization module of instruments
designed for the analysis of biological specimens typically adds protons to the molecules
to be analyzed, thus conferring the charge necessary for analysis. The movement of these
ions through the mass spectrometer is dependent on both mass and charge and is typically
measured as mass over charge (m/z) ratio. Because the direct mass is not measured, the
real mass of the ions can only be determined if the charge state can be determined.
Determination of charge state is possible because of naturally occurring isotopes, but
becomes more difficult with increasing size
and charge states. (Zubrig 2008 Peptidomics)
The use of a reflectron, also known as an
electronic or ion mirror, is used in TOF MS
instruments to reflect ions and substantially
increases resolution and the ability to
determine the mass of larger and more highly
John B. Fenn

Koichi Tanaka

charged molecules. (Hortin 2006) The
(http://nobelprize.org)

importance of MS analysis of biological

molecules methods was highlighted when Koichi Tanaka and John Fenn were awarded
the Nobel Prize for chemistry in 2002 for the invention of MALDI and ESI respectively.
The most common types of mass spectrometers used for proteomic analysis are
quadrupole (Q), ion-trap, time-of-flight (TOF), and Fourier-transform-ion cyclotron
resonance (FT-ICR) instruments or their combinations (e.g., hybrid instruments such as
Q-TOF, combining quadrupole and time-of-flight detectors). All mass spectrometers
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measure m/z, and so they all require that species to be analyzed carry a charge. Ionization
of biomolecules can be achieved using either MALDI or ESI. With MALDI, sample is
co-precipitated with a matrix onto a sample plate. Ionization is achieved by pulsing a
laser at the co-precipitated sample. The matrix absorbs the laser energy and desorbs from
the plate, taking the charged protein sample with it. Molecules ionized using this method
carry single charges. With ESI, charged droplets are sprayed from a high voltage needle.
A stream of nitrogen gas evaporates the solvent, leaving the singly or multiply-charged
proteins in the gas phase. (Figure 1.1) (Zubrig 2008 Peptidomics)
High resolution mass spectrometers allow for accurate reading of fragmentation
data caused by collision of the peptides of interest with inert gas, typically called peptide
mass fingerprinting. This fragmentation mainly occurs at peptide bonds and yields a
series of overlapping fragment ions that include either the C- or N- terminus of the
peptide. The m/z differences between fragments differ by the exact weight of an amino
acid and permits deduction of the amino acid sequence of that peptide. (Papayannopoulos
1995) This collision-induced method of fragmentation is referred to as tandem MS or
MS/MS. The traditional proteomics role of MS/MS was limited to identifying the
proteins in spots or bands from one- or two- dimensional polyacrylamide gels. 2D-GE
has numerous limitations as a method for visualizing and/or resolving many types of
proteins, including small proteins, hydrophobic proteins and even some soluble proteins.
(Cutillas 2008)
MS has revolutionized protein identification by pushing sensitivity up by several
orders of magnitude over previous detection and sequencing methods, and has shortened
the identification process from many hours to just a few minutes. Using ESI MS/MS
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methods, identification of several hundred peptides per day can be achieved. The purity
and amino acid composition of the peptides being analyzed determines their ionization
efficiency. Some combinations of amino acids don’t ionize well, and so as the mixture of
peptides in a given sample competes for ionization, the signal of some peptides will be
suppressed. Sensitivity also decreases as the complexity of the sample increases. If a

Figure 1.1. Principles of MS – MALDI (A) and ESI (B) Ionization methods for peptides.
(C) A typical MS experiment. The left-hand panel shows a peptide mass fingerprint. A
survey scan measures the peptide masses, which can then be inspected for peaks of interest.
The right-hand panel demonstrates a determination of peptide sequence. Using MS, the
peptide peak to be sequenced is selected from the survey scan and fragmented, usually by
collision with gas. The fragment masses are determined by MS/MS. The peptide sequence
can be deduced from the fragment masses. Because the fragmentation spectra rarely
represent fragmentation between every peptide bond, de novo protein sequencing from the
spectra alone is often not possible. Therefore, rather than trying to read the sequence from
the mass spectrum, the fragmentation patterns are usually submitted to a database search
engine for identification. This search compares the observed fragmentation pattern with
theoretically expected peptide fragmentation patterns of the proteins predicted from the
compiled genome databases. (Zübrig 2008 Peptidomics)
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sample is dominated by high abundance peptides, it is difficult to detect the lower
abundance peptides. This is a situation typical for serum or plasma samples where the
protein concentration varies over more than ten orders of magnitude. Additionally, both
sensitivity and mass accuracy drop off sharply with increasing size, so the most effective
mass window is between 1 and 5 kDa. Because of this, proteins are usually digested into
peptides prior to analysis with MS. (Zubrig 2008 Peptidomics)
In order to maximize the number of molecules analyzed in a complex sample,
capillary liquid chromatography (cLC) is often coupled to ESI MS. This provides a
powerful separation step that allows separation of analytes and increases sensitivity.
(Abersold 2003, Issaq 2002, Zurbig 2006) Using cLC-MS, information on hundreds of
polypeptides from an individual sample can be obtained relatively quickly. There is a
great potential for finding novel biomarkers within this information. The physiological
role of any potential biomarkers found using cLC-MS remains unknown unless their
amino acid sequence can be determined. Because these biomarkers are most likely low
molecular weight (LMW) and present in relatively low quantities in the serum, they
cannot be easily isolated or purified. Potential biomarkers may even be fragments of
larger proteins, representing both those that are proteolytically cleaved as well as those
that are post-translationally modified. (Zubrig 2008 Peptidomics) Identification of such
biomarkers requires de novo sequencing. A semiquantitative measurement of two
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different samples can be made by measuring the peptide signal intensity. This can be
done without using labels as long as the experimental conditions are constant and the
sample analysis order is randomized. (Radulovic 2004, Johansson 2006, Sköld 2008)

Figure 1.2. Schematic of Qstar QqTOF Mass Spectrometer. Q0 and Q2 are rf-only
quadupoles used to focus ions into the next part of the instrument. Q1 may be operated in the
rf-mode only (MS) or in the mass selective mode (CID MS/MS). Mass resolution is 10002000. TOF analyzer with ion mirror has a Mass resolution ~10,000. (from
www.iccs.edu/QSTAR w.pdf)

Serum Proteomics for Biomarker Discovery
There are two main challenges in serum proteomic analysis. One is a resolution
challenge and results from the large number of different molecular species present in
most biological samples. The second is a dynamic range challenge due to the
considerable difference in concentrations between the most and least abundant molecular
species present in the sample. (Finch 2008) As an example of this, consider a sample of
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human plasma: over 95% of the total mass of the proteins in plasma is made up of 12
species, namely human serum albumin, IgG, IgA, IgM, transferrin, fibrinogen,
apolipoprotein A-I, apolipoprotein A-II, haptoglobin, α-1 antitrypsin, orosomucoid (α-1
acid glycoprotein), and α-2 macroglobulin. (Finch 2008) A breakdown of a small
fraction of one of these peptides could overwhelm the detection of smaller, unknown
peptides. (Skold 2002, Svensson 2003) Plasma and serum are highly complex body
fluids that contain lipids, carbohydrates, amino acids, nucleic acids, hormones, and
proteins. (Zubrig 2008 Biomarker) The information found in serum could describe the
health state of an individual. (Thadikkaran 2005) The search for serum biomarkers is
based on the assumption that “disease” correlates with an altered state of information
circulating in the blood. (Zubrig 2008 Biomarker) Many types of molecules function as
signaling molecules. It is likely that the low-molecular weight, low-abundance fraction
of the human serum proteome is where the novel biomarkers are to be found. (Liotta
2003, Meng 2007)
It is hoped that the identity of potential biomarkers will provide insights into the
pathology of the disease process. An NIH study group settled on a single definition of
what a biomarker is: “A characteristic that is objectively measured and evaluated as
indicator of normal biologic processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention.” (Biomarkers Group 2001) A biomarker is a molecule that
allows for detection of changes in physiological state of an individual due to disease,
treatment, or exposure to any other environmental factor that might affect the health of
the individual. These insights could possibly lead to the development of new tools for
detection and/or treatment. (Zubrig 2008 Biomarker) Biomarkers have the potential to
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identify pathological processes before they become symptomatic and could be used to
screen for disease, even if that disease was at an asymptomatic stage. (Srinivas 2001)
Biomarkers could also be used as prognostic markers to predict the progression of the
disease, as stratification markers to predict the likely response to a treatment, or as
efficacy markers to monitor the success or failure of treatment. (Zubrig 2008 Biomarker)
When diseases have similar symptoms, as is the case with Alzheimer’s disease and
vascular dementia, biomarkers can be used to discriminate between them. (de Jong 2006)
In most cases, proper diagnosis is required for effective treatment.
There are currently many biomarkers used diagnostically in medicine. One of the
earliest and most widely known is prostate-specific antigen, still used as a screen for
prostate cancer. There are an estimated 198,100 new cases of prostate cancer every year.
This accounts for nearly 30% of all the cancers diagnosed in men. There were an
estimated 39,200 deaths due to prostate cancer in 1998. (Grenelee 2001) Kuriyama et al
developed an assay to measure prostate-specific antigen (PSA) in human serum and
subsequent studies demonstrated the correlation between serum levels and prostate cancer
incidence. (Kuriyama 1980, Catalona 1991) Since then, PSA has been the most
commonly used tumor marker for prostate cancer. Conflicting results have been reported
as to the accuracy of PSA as a biomarker with sensitivities (true positives) being reported
in the 67-100% range with an average of 72% and reported specificities (true negatives)
ranging from 18-100% with an average of 93%. The positive predictive value was
reported in the 17-57% range with an average of 25%. These results suggest that when
abnormal PSA findings are reported, there is a 1 in 4 chance that there is cancer, but
when the PSA levels are normal the chance of missing cancer is about 1 in 10. (Kishor
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2003) The currently accepted cutoff for PSA screening is a serum level of >4 ng/ml.
Using this cutoff, 62% of prostate cancers are detected, but 38% of cancer patients have
PSA below this level. This is partially due to increases in serum PSA levels due to noncancerous prostate conditions, or advancing age. Regardless of the limitations, PSA
serum screening has aided in early diagnosis for prostate cancer, and a decrease in patient
mortality.
In the Surveillance, Epidemiology, and End Results (SEER) database, the
percentage of prostate cancer patients with metastatic (distant) diseases at the time of
diagnosis decreased from 16% in the period from 1985-1989 to 4% for the period from
1996-2004. The SEER data also show that the relative 5-year survival rate for metastatic
prostate cancer is only 31.7%, while that for localized/regionalized prostate cancer is
98.9%. Indeed, the overall 5-year survival rate increased from 76.1% for the period
1984-1986 to 98.9% for the period 1996-2004. It is likely that the increased use of PSAbased screening is at least partially responsible for this marked improvement in both early
diagnosis and overall survival rate. (Loeb 2007, Surveillance 2008) The continued
success of PSA as a diagnostic screening tool despite its limitations has demonstrated the
value of serum biomarkers for disease.
In rheumatoid arthritis (RA) it is important to discriminate between ‘slow’ and
‘fast’ progressing disease to allow treatment with appropriate drugs. If it is determined
that a particular case of RA is of the faster progressing variety, more aggressive drugs are
used to decrease the level of joint destruction in that patient. (Liao 2004) This assessment
can be accomplished with biomarkers for RA. Biomarkers, in combination with the
collagen turnover rate, can also be used to follow the effectiveness of RA treatment drugs
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over time. (Torikai 2006 Infliximab, Torikai 2006 Methotrexate) Early detection is
crucial for control and prevention of many diseases. These diseases include, but are not
limited to RA, Parkinson’s disease, Alzheimer’s disease, and cancer. (Dorsey 2006,
Sunderland 2006, Wulfkuhle 2003)
Because the potential for biomarkers is so great, many groups are searching for
biomarkers for many different diseases. A compilation of the serum/plasma biomarkers
identified in 24 studies using MS is shown in Table 1.1. Many of the biomarkers are
fragments or isoforms of larger and abundant serum proteins. This extensive, but not
comprehensive, list demonstrates the great strides that have been made in recent years
towards novel biomarker discovery.

Disease or process

m/z

Change

Peptide/Protein identity

Reference

Studies of serum specimens
Myocardial infarction

Alcohol use

Not listed
2021

C3f fragments: 1865, 1778, 1691, 1563,
1450, 1349, 1212

5900

Fibrinogen -chain (576–629

7800

Apolipoprotein A-II (28–94)

28 000
Ovarian cancer

Inter- -trypsin inhibitor

7800

Apolipoprotein A-II (28–94)

Metastatic prostate cancer

Ovarian cancer

9200

Marshall 2003

Nomura 2004

Apolipoprotein A-I

3272
28 043

Renal cancer

Fibrinopeptide A and fragments

Zhang 2004

Apolipoprotein A-I
Haptoglobin 1-chain

11 400

Serum amyloid A (des-RS)

11 500

Serum amyloid A (des-R)

11 680

Serum amyloid A

11 488

Serum amyloid A isoform

11 537

Serum amyloid A isoform

11 639

Serum amyloid A isoform

11 680

Serum amyloid A

15 100

Hemoglobin -chain

15 800

Hemoglobin ß-chain
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Tolson 2004

Le 2005

Woong-Shick 2005

Prostatic disorders
Nasopharyngeal cancer
Breast cancer
Retrovirus infection

Breast cancer

Apolipoprotein A-II

Malik 2005

11 600

Serum amyloid A

Cho 2004

11 800

Serum amyloid A

8946

8116

C3a (des-9 residues)

8926

C3a (des-R)

11 700

1-Antitrypsin

fragment

11 950

Haptoglobin-2 fragment

19 872

Haptoglobin-2 fragment

6647

Apolipoprotein C-I

8936

C3a

9192

Haptoglobin

1-chain

28 284

Apolipoprotein A-1

81 763

Transferrin

2740

Benzene exposure

7700

Platelet factor-4

9300

Connective tissue-activating peptide-III

Cancers (prostate, bladder,
or breast)

Semmes 2005

Goncalves 2006

Diet change

Ovarian cancer

Li 2005

2-HS-glycoprotein

B-chain

13 900

Transthyretin and 12 900

15 900

Hemoglobin ß-chain

28 000

Apolipoprotein A-I

79 000

Transferrin

Mitchell 2005
Vermeulen 2005
Kozak 2005

1537

Fibrinopeptide A and fragments: 1466, Villanueva 2006
1351, 1264, 1207, 1078, 1020, 906, 758

3261

Fibrinogen -chain fragments: 3190,
2931, 2768, 2553, 2379, 2816, 3239,
2659

2021

C3 fragments: 1865, 1778, 1751, 1691,
1563, 1450, 1349, 1212, 1056, 942

3201

C4a fragments: 2704, 2305, 1763

1896

C4a fragments: 1740, 1627, 1499

3971

Inter- -trypsin inhibitor fragments:
3272, 2724, 2627, 2358, 2271, 2184,
2028, 1789, 998, 842 (or )

3157

Inter- -trypsin inhibitor fragments: 2115

3377
3182

None Apolipoprotein A-I fragments: 1808
Apolipoprotein A-I fragment and 1971

Table 1.1 Biomarkers identified in 24 published studies using MALDI-TOF or SELDI-TOF MS
(18 studies examined serum specimens and 6 studies examined plasma). (Hortin 2006)

In order to preserve the integrity of the information in a serum sample, the fewest
number of processing steps possible should be employed. In fact, the ideal situation
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would be one in which a crude, unprocessed sample is used for investigative analysis.
Unfortunately, this is not possible with most body fluids. Easily accessible body fluids
like serum have proteins that are already in solution, but serum also contains a complex
mixture of molecules covering a wide range in size, concentration, polarity, and
hydrophobicity. Because of the extreme range in concentration of the constituent
molecules found in serum, the most abundant molecules must be removed to be able to
visualize the less abundant molecules using MS. Removal of the larger highly abundant
proteins, such as albumin, can be accomplished using affinity columns (Zolotarjova 2005,
Bailes 2008), ultrafiltration, or organic solvent precipitation (Merrell 2004). Other
methods used to process samples include size exclusion, anion exchange (Kaiser 2003),
and reverse-phase separation (Wittke 2003). After sample preparation, a separation step
is generally employed to reduce the complexity of the sample to maximize the sensitivity
of ionization and subsequent MS analysis. (Zubrig 2008 Peptidomics)

Peptidomics
Peptides, like proteins, are formed of chains of various amino acids linked
together through amide bonds. The main difference between proteins and peptides is the
number of amino acids in the chain; proteins have more and are long, and peptides have
fewer and so are short. There is no specific, accepted length at which a polymer of amino
acids ceases to be a peptide and begins to be a protein. Some people apply a cutoff
length of approximately 50 amino acids in length, but this has been disputed. Some
‘proteins’ (such as insulin) fall close to the upper limit of this definition, and some
peptides (e.g. amyloid beta peptide) are often considered ‘proteins’ despite falling below
this cutoff. Another suggested way to differentiate between proteins is by mass; with
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proteins having masses above 10 kDa and peptides having masses below 5 kDa.
(Schrader 2001, Schulz-Knappe 2005) However, this definition is not universally
accepted or applicable; ubiquitin is considered a protein and has a mass of just 8 kDa,
many peptide hormones like insulin and IGF have masses below 10kDa, others like
PDGF have larger masses. (Cutillas 2008) Because both of these considerations are
somewhat arbitrary, it has been suggested that the scientific community as a whole
ascribe to the definition that “a peptide is a poly-amino acid molecule without tertiary
structure; on gaining defined structure, it is a protein.” (Zubrig 2008 Peptidomics) This
has yet to become the standard.
The first successful studies of the peptidomes of various biological samples were
reported over 60 years ago. These samples included urine (Baar 1956), blood (Jolley
1965), and brain tissue (Hughes 1975) and were accomplished using mainly
chromatography and hard-ionization pre-LC-MS techniques. (Lucas 1969) The study of
peptides (peptidomics) is important in the search for novel biomarkers in serum. Specific
kinds of peptides function in cell to cell communication in an autocrine, paracrine, or
endocrine (systemic) manner. (Strand 2003) In addition, since peptides can often
redistribute between the various compartments of the body, it is probable that peptide
content within the serum will mirror changes made by disease. (Zubrig 2008
Peptidomics) The serum peptidome then provides an integrated sample, being comprised
of secreted and intracellular peptides from throughout the body. (Griffiths 2008) It is
likely that the low-abundance fraction of the human serum peptidome will prove useful in
the search for novel biomarkers for disease. (Liotta 2003, Meng 2007)
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Change from
Healthy State

Peptidomic
Search for
disease-specific
biomarkers

Secretion,
protection

Trophic peptides
and PTMs

Necrosis

Proteases
and cleavage

Peptide
Fragments

Phagocyte
recruitment

Inflammation,
fibrosis

Cytokines,
chemokines and
growth factors

Metabolism, upregulation
of protein expression

Figure 1.3. The possible sources of disease-specific peptides in the serum proteome. Disease causes
a change in tissues and/or organs from their normal healthy state. Disease may induce posttranslational
modifications (PTMs), proteolytic cleavage, or other responses. (Adapted from Griffiths 2008)

Thousands of peptides have been tentatively identified in plasma. (Hortin 2006, Omenn
2005) The majority of the peptides in serum samples are bound to carrier molecules,
primarily serum albumin. (Araujo 2008) The abundance of carrier molecules is high
enough compared with the concentration of free peptides in the serum that even if the
binding affinity between a carrier molecule and a free peptide is low, the peptide is more
likely to exist in a bound form than a free form in the serum. (Figure 1.4) Because larger
proteins have longer half-lives in the serum (Table 1.2), the binding of smaller peptides to
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Figure. 1.4 Low-abundance molecules such as flavonoids (left) and protoporphyrins (right),
with low-affinity for albumin, will nevertheless exist almost entirely in complexed association
with albumin in the bloodstream on account of albumin's overwhelming abundance. The large
albumin concentration amplifies the effective affinity constant, Ke, to Ke 90 for flavonoids
and Ke 5600 for protoporphyrins, corresponding to 98.9% and 99.98% probability that the
biomarker will be complexed with albumin for flavonoids and protoporphyrins, respectively.
(Araujo 2008)
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Fig. 1.5. Biomarkers in the blood stream. A low-abundance biomarker enters the blood stream
at a constant rate, αb. Once in the bloodstream, a proportion of the biomarker will bind to
carrier proteins (φbC, while the remainder resides in the bloodstream in a free (unbound) form
(φb). (Araujo 2008)

larger ones gradually but effectively amplifies their total concentration in serum.
Peptides that do not bind to larger molecules are cleared from the serum by the kidneys
within hours, or even minutes. (Figure 1.5) Changes in disease state that are reflected in
the serum will not be instantly reflected in the total levels of the biomarker concentration.
Rather, the secretion of biomarker into the serum by diseased tissue will gradually be
bound by carrier molecules, increasing their half-life dramatically and slowly increasing
their total concentration. (Araujo 2008) These complex mixtures of bound peptides have
not been thoroughly studied, but if each molecule of albumin binds 1 peptide, there exists
a potential capacity of more than 500 µmol/L of bound peptides. (Omenn 2005) Thus,
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when searching the serum proteome for potential biomarkers, it is essential to include that
fraction that is bound to larger carrier proteins.

Protein

Half-life

Albumin
Transferrin
Fibrinogen
1-Antitrypsin
Apolipoprotein A-I
Apolipoprotein A-II
Transthyretin
Retinol-binding protein
Immunoglobulin -chains
Immunoglobulin -chains
ß2-Microglobulin
Fibrinopeptide B
Parathyroid hormone

15–19 days
7 days
2.5 days
4 days
5 days
5 days
1–2 days
10–12 h
3–6 h
2–4 h
1–2 h
<10 min
<5 min

Molecular mass Reference
66 438
77 000
340 000
55 000
28 079
8691
54 400
21 066
48 000
24 000
11 800
1556
9425

(102)
(102)
(102)
(102)
(111)
(112)
(113)
(113)
(64)
(64)
(102)
(38)
(89)

Table 1.2. Half-lives of proteins and peptides in the circulation. (Richter 1999)

Summary
This introduction has outlined both the ever-increasing need for novel biomarkers
for disease and some of the technologies currently employed to identify prospective
biomarkers. The large number of biomarkers reported in Table 1 show that previously
described methods have produced a promising number of potential candidates, but not
necessarily a high number of exciting results. Most of the potential biomarkers identified
are fragments of large, highly abundant proteins found within the blood. Many of these
are well-characterized and not likely to provide new insights into the pathology,
progression, or treatment of disease. Novel biomarkers that are less abundant are likely
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to be more informative. The low molecular weight component of the serum proteome is
a likely place to begin the search for novel and informative biomarkers for disease. For
this reason, we have chosen to focus our search for novel biomarkers within this subset.
Several of the challenges associated with the search for biomarkers in the lowabundance, low-molecular weight fraction of the serum will be discussed in detail in the
following chapters. The second chapter outlines several methods that were developed to
address issues encountered in sample preparation, data normalization and alignment, and
identification of potential biomarker peptides using MSMS. The third and fourth
chapters are examples of our search for biomarkers for preterm birth and preeclampsia.
While our initial results seem promising, we realize that what has been found so far is
just the tip of the iceberg when it comes to potential biomarkers for these conditions.
There is still much to be done with regards to searching, sequencing, and validating these
potential markers in order for them to be useful in a diagnostic setting, but these results
represent a very good start towards a non-invasive test for these and other diseases that
are very hard to diagnose very far in advance of onset of the diseases.
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Chapter 2 – Methods
Part I – Analysis of Low-Abundance, Low-Molecular-Weight
Serum Proteins Using Mass Spectrometry
Abstract
To detect diseases early in the general population, new diagnostic approaches are
needed that have adequate sensitivity and specificity. Recent studies have used mass
spectrometry (MS) to identify a serum proteomic pattern for breast and ovarian cancer.
Serum contains 60-80 mg protein/mL, but 57-71% of this is serum albumin, and 8-26% is
γ-globulins. These large proteins must be depleted before smaller less-abundant proteins
can be detected using MS, but because serum albumin is known to act as a carrier for
smaller proteins, removal of these molecules using columns or filtration may result in the
loss of molecules of interest. The objective of this study was to develop a reproducible
method to deplete serum samples of high-abundance proteins in order to analyze the lessabundant proteins present in serum. We used organic solvents to precipitate the large
proteins out of solution. We also predicted that this would cause many smaller proteins to
dissociate from their carrier molecules, allowing for detection of a larger number of small
peptide and proteins. These treated samples were analyzed using capillary liquid
chromatography coupled with electrospray ionization mass spectrometry. Analysis
demonstrated reproducible results. Acetonitrile treatment clearly released many carrier
bound molecular species and was superior to ultrafiltration alone for serum proteomic
analysis.

22

Introduction
Many diseases, such as cancer, do not show obvious clinical symptoms until the
disease is in advanced stages and difficult to treat successfully. Detection of such diseases
in early stages can greatly reduce disease-related mortality. (Li 2002, Petricoin 2003
Clinical) Traditionally, researchers have searched for disease biomarkers using a one-ata-time approach. However, because of the complexity of many diseases, it is very likely
that the use of multiple biomarkers (protein pattern diagnostics) in screening and
diagnosis will be necessary to produce unequivocal results. (Li 2002, Petricoin 2002
Clinical)
Biomarkers are often low molecular weight proteins secreted into the blood
stream as a result of the disease process. (Petricoin 2002 Clinical) Employing mass
spectrometry (MS) in serum proteomic pattern diagnostics has a very high potential for
discovering new, relevant disease-related biomarkers. (Petricoin 2003 Counterpoint)
Serum contains a total of 60–80 mg/mL of protein, with a concentration range spanning
at least nine orders of magnitude. An estimated 10,000 different proteins typically exist in
serum, the majority of which are low molecular weight species. (Adkins 2002) The
complexity of serum makes it a very informative source for developing a proteomic
pattern, however, 65–97% of serum protein is serum albumin and immunoglobulin. The
presence of these highly abundant proteins makes detection of the smaller, less-abundant
serum proteins difficult. (Adkins 2002, Govorukhina 2003)
Some have used cibacron dye and protein A/G columns to remove serum
albumin and immunoglobulin from serum effectively, allowing detection of biomarkers
present at very low concentrations. (Govorukhina 2003, Ahmed 2003) Molecular weight
cutoff filters have also been evaluated in separating the large, abundant proteins from the
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smaller, less abundant ones. (Georgiou 2001) Albumin serves as a transport protein that
binds, and thereby accumulates many low-abundance biomarkers that would otherwise be
cleared from the blood by the kidney. (Petricoin 2002, Adkins 2002, Liotta 2003)
Consequently, removal of serum albumin by filtration also inadvertently removes many
small proteins and peptides of interest.
Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS),
surface-enhanced laser desorption ionization mass spectrometry (SELDI-MS), and liquid
chromatography-coupled to online electrospray mass spectrometry (cLC-MS) are
methods that have been used for protein pattern development for several diseases.
MALDI-MS employs no separation, and it is sensitive to organic and inorganic
contaminants as evidenced by signal background problems. (Li 2002) SELDI-MS is an
affinity-based method that uses various stationary sorbants (hydrophobic, ionic, cationic,
and metal binding) to selectively bind proteins of interest. Because many biomarkers are
present at very low concentrations in biological fluids, they are not likely to be
immobilized on the biochips used in SELDI-MS but may be washed away with all of the
other protein species that do not bind to the active surface. (Diamandis 2003, Banez
2003) Current SELDI instruments are also severely limited in their resolution. cLC-MS,
while not as high throughput as MALDI-MS or SELDI-MS, is more effective for the
detection of low-molecular weight, low-abundance proteins and peptides in a complex
mixture.
In this report, we hypothesized that using acetonitrile precipitation, which has
been shown to effectively precipitate large, abundant proteins out of serum, (Alpert 2003)
is a superior method to remove serum albumin and immunoglobulin from serum because
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acetonitrile not only denatures these large proteins allowing for their removal but should
also cause the small, low-abundance proteins and peptides normally bound to these
carrier proteins to dissociate, thus making them available for detection using cLC-MS.
We report that this procedure was effective and allowed for the visualization of small
proteins and peptides from serum. An average of ~4,000 ionized species under 2.5 kDa,
as well as some proteins between 2.5 and 10 kDa, were detected per serum sample
analyzed.

Materials and Methods
All reagents were purchased from Sigma (Saint Louis, MO)

Sample Collection
After Institutional Review Board (IRB) approval was obtained at the University
of Utah (IRB # 10535), serum samples were obtained from women who presented to the
labor and delivery suite with a pregnancy at ≥ 36 weeks gestation. Blood was obtained
by antecubital venipuncture and after centrifugation at 3,500 rpm for 15 minutes, serum
was collected, aliquoted and frozen at -80º C until further processing. Samples were also
obtained at the BYU Student Health Center from healthy male volunteers.

Acetonitrile Precipitation
Briefly, the ‘standard’ method (Alpert 2003) involved adding two volumes of
HPLC grade acetonitrile to 1 volume serum followed by gentle mixing. After standing at
room temperature for 30 minutes, samples were spun for 4 minutes at 12K rpm. An
aliquot of supernatant was then lyophilized to 50 μl. The sample was reconstituted to
original volume by addition of water.
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The ‘modified’ method involved adding two volumes of HPLC grade acetonitrile
(400 μl) were added to 200 μl serum, vortexed vigorously for 5 seconds, and allowed to
stand at room temperature for 30 minutes. Samples were then spun for 10 minutes at 12K
rpm in an IEC Micromax RF centrifuge at room temperature. An aliquot of supernatant
(550 μl) was then lyophilized to 200 μl in a vacuum centrifuge (LABCONCO CentriVap
Concentrator). Supernatant protein concentration was determined using a Bio-Rad
microtiter plate protein assay according to manufacturer instructions. An aliquot
containing 4 μg protein was transferred to a new microcentrifuge tube and lyophilized to
near dryness. Then 20 μl 88% formic acid, 2 μl 5 pmol/μl mellitin, and 2 μl 5 pmol/μl
[Glu1] fibrinopeptide were added to lyophilized samples. Samples were brought to 40 μl
with HPLC water.

Centrifugal Ultrafiltration
1 ml of serum was diluted with 5 ml of 25 mM ammonium bicarbonate and added
to an appropriately conditioned 30 K molecular weight cutoff (NMWL) centrifugal filter.
After centrifugation, the filtrate was lyophilized to dryness and reconstituted to 40 µl
with 20 µl 88% formic acid and 20 µl water. The retentate was reconstituted to its
original 1 ml volume with HPLC grade water. Additionally, 200 µl of retentate were
subjected to acetonitrile precipitation and 1 µg of protein of each sample was loaded onto
the column according to procedures outlined below.

cLC-MS Analysis
Capillary liquid chromatography, to fractionate or separate peptides and proteins,
was performed using a 15 cm x 250 um i.d. capillary column, packed in-house using
POROS R1 reversed-phase media (Applied Biosystems, Framingham MA), employing a
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2.2%/min gradient to an organic concentration of 60% acetonitrile in 0.1% formic acid,
followed by a 3.5%/min gradient up to a concentration of 95% organic phase.
Chromatography used an LC Packings Ultimate Capillary HPLC pump system, with a
FamOS autosampler (Dionex Corp), controlled by the mass spectrometer software
(Analyst). The LC is coupled directly to the MS. Effluent from the capillary column was
directed into a QSTAR Pulsar i quadrupole orthogonal time-of-flight mass spectrometer
through an IonSpray source (Applied Biosystems). Data were collected for m/z 500 to
2500 over the entire range of the chromatogram (55 min). Data collection, processing
and preliminary formatting was accomplished using the Analyst QS software package
with BioAnalyst add-ons (Applied Biosystems).

Normalization of Elution Times
Small differences in elution time were accounted for by normalizing them to the
elution time of a molecular species with a unique m/z value, common to all samples.

Results and Discussion
Evaluation of Protein Precipitation Approaches Our goal was to develop a protein
precipitation method that had sufficient reproducibility to allow for accurate quantitative
serum proteomic analysis in an effort to identify molecular species that differed between
healthy and diseased states. The adequacy of this method was tested using cLC-MS.
Additionally, we were interested in determining the residual molecular species and their
molecular weights after a precipitation procedure.
Organic solvents have long been used to precipitate proteins. Unlike other
techniques, such as ultrafiltration or dialysis, this technique will typically result in many
smaller proteins and peptides being released from large carrier proteins.
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In our initial study two techniques were evaluated. The first was a previously
described method that represented one of the first approaches to serum preparation for
global serum proteomic analysis using MS. The second was a modification of that

Standard Method
Modified Method
Mixing after addition of Acetonitrile
Gentle Mixing

Vortexing

cloudy supernatant

clearer supernatant

higher protein concentration

lower protein concentration

inconsistent protein concentration

consistent protein concentration

Centifugation
4 min. at 12,000 rpm

10 min. at 12,000 rpm

cloudy supernatant

clearer supernatant

Concentrated Volume of Supernatant
50 μl

200 μl

precipitate forms

no precipitate forms

Table 2.1. Optimization of acetonitrile precipitation. The table outlines the two
methods tested and their respective relevant findings.

technique. The methods are described in detail in the Methods section and summarized
in Table 2.1. The results of the two approaches are shown in Figure 2.1. The previously
described or 'standard' method resulted in a mean protein level of 0.240 ± 0.124 mg/ml.
The modified method produced a mean protein concentration of 0.028 ± 0.0006 mg/ml
which was significantly less than the 'standard' method (Students Unpaired t-test: P=3.1 x
10-5). Moreover, protein concentrations remaining after the modified method were far
less variable (CV method 1 = 51.7%, CV method 2 = 21.4%). This reduction was an
improvement, but admittedly did not completely eliminate variability. It is beyond the
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aims and scope of these experiments to determine whether the two methods resulted in
different proteins being precipitated or in more efficient removal of the same proteins.

Figure 2.1. Protein yield comparison of standard and modified acetonitrile
precipitation. The left column shows that the standard method varied greatly in protein
yield. As shown in the column on the right, the new modified method resulted in a more
reproducible protein yield.

In addition, the original method left a cloudy solution after centrifugation, suggesting that
some of the variability may result from an inadequately long or forceful centrifugation
step. This unresolved precipitate is likely to be difficult to measure accurately in a
protein assay and may contribute to the marked variability of residual protein
concentration.
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Further reductions in the liquid portion of the supernatant, in particular taking the
sample to dryness, resulted in a residue that was no longer appreciably soluble in the cLC
mobile phase solvent.

cLC-MS Evaluation of Residual Proteins
Because of the improved reproducibility of the modified method, it was used for
all subsequent experiments. The final volume of 200 μl was too large to inject onto our
capillary column. Therefore, immediately prior to specimen introduction into the cLCMS system, a volume of solution containing 4.0 μg of protein was aliquotted and
concentrated to near dryness, avoiding complete dryness. Any precipitate that formed
upon concentration was resolubilized by the addition of 20 μl of 88% formic acid. There
was no appreciable protein loss in this step (data not shown).
This precipitation method was further evaluated to determine the molecular
weight range and number of molecular species present after treatment. Given the large
number of molecular species, the whole elution interval was divided into five minute time
frames and the mass spectra were averaged for that period. Then the LCMS reconstruct
tool in BioAnalyst was applied to the averaged spectrum. Output from the several 5
minute intervals was compiled to capture all species over the entire sample run. Figure
2.2 represents the average of 49 different specimens. While the most abundant species
were below a MW of 2,000 (Panel A), many species with MW >2,000 daltons (Panel B)
were still present.
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Figure 2.2. Molecular weight distribution of species observed in acetonitrile
supernatant. cLC-MS was used to analyze 49 serum specimens after acetonitrile
precipitation. A) This histogram shows the distribution of all molecular species ranging
from 500 to 5000 Daltons. B) This histogram shows the distribution of all molecular
species ranging from 5 to 10 kD. The majority of the species present were below 2000
Daltons.

It is important to note that close comparison of the actual unmanipulated mass spectra to
the software LCMS reconstructed data demonstrated that the LCMS reconstruct tool
occasionally omitted species, and did so variably, making it unreliable for use in clinical
studies where quantification is critical.
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Value of ACN Precipitation
The effects of acetonitrile precipitation of serum proteins were evaluated by direct
comparison of pre- and post-precipitation cLC-MS chromatograms. Comparisons of
untreated and treated serum demonstrated that many more molecular species were
observable by MS after treatment. This is evident in panels A and B of Figure 2.3 which
show an expanded number of molecular species in the total-ion chromatogram (TIC) after
treatment (panel B). Moreover, the mass spectrum of the untreated specimen was
dominated by the extensive envelope (See panel C), which peaked between an m/z of
1300-1400, representing a species with molecular weight of 60-70 kDa (most likely
albumin or related compounds) which masked many molecular species. Even the region
of lower m/z (as shown in the insert of panel D) had more species revealed by ACN
treatment. These findings appear to confirm the hypothesis that organic solvent
precipitation of proteins would also release smaller, protein-bound species. While it is
true that larger proteins present in the serum specimen are sacrificed by ACN treatment,
it is also true (as clearly evident in panel E) that higher molecular weight species are
obscured by the highly abundant albumin and that lower molecular weight species are
both more abundant and more observable after treatment (see panel C and D as well as
E). In summary, the ACN pre-treatment actually provides broader mass spectral access
to the serum proteome and makes more likely the development of an informative and
diagnostic pattern for defining differing states in the human. It should also be noted that
most growth, stimulatory, regulatory and pathology-responsive factors are small proteins
and peptides. Consequently, the additional ability of serum proteomics to actually define
the mediators of disease may be more successful after treatments that more fully expose
this lower molecular weight sub-proteome.
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Figure 2.3. Comparison of serum protein (1µg) before and after acetonitrile precipitation.
Total ion chromatograms (TIC) for serum proteins before (A) and after (B) acetonitrile are
presented. The averaged mass spectra for the cLC elution (taken from 24 to 25 min) of a serum
specimen prior to ACN precipitation (C) and after ACN precipitation (D) are shown. Panel C
contains an inlay that shows the protein mass graph of the Baysein protein reconstruct performed
on the mass spectrum from 900 m/z to 2500 m/z. The inlay in panel D shows the expanded (500
to 1000 m/z) mass spectra overlay of the pre and post samples. E) The overlay of the mass
spectra for species present between 25 and 26 min of elution for the two samples is shown.
Before ACN precipitation is shown in blue, after ACN precipitation is shown in red.

Ultrafiltration vs. Precipitation
Centrifugal ultrafiltration is a common method used to remove serum albumin,
immunoglobulins and other abundant, high molecular weight proteins from a serum
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specimen. (Tirumalai 2003) Such treatment is often necessary before chromatography or
capillary electrophoretic techniques can be employed. Although this method is selective
for low molecular weight peptides and proteins in a sample, the resulting filtrate may not
allow for a thorough examination of the entire low molecular weight serum proteome.
Small proteins and peptides are commonly bound by large carrier proteins to both
moderate their free and biologically active concentration and to prevent them being
rapidly cleared from the blood by the kidney. The experiments described in the previous
section suggested strongly that there was an increase in low molecular weight species
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Figure 2.4. LCMS of acetonitrile supernatant compared to 30K NMW filtrate. Total ion
chromatograms of ACN-precipitated serum (A) and reconstituted filtrate (B) are shown. Panels C
and D show the averaged mass spectra overlay from 18 to 27 min cLC elution for the serum and
the filtrate respectively. ACN-precipitated serum is shown in blue, the filtrate is shown in red.
Comparison of panels C and D, shows that the ACN precipitation method was superior to the
centrifugal ultrafiltration technique in both number of low molecular weight species and intensity
of peaks.
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after the addition of ACN to denature serum proteins. A second line of evidence for this
is provided by comparison of the ACN precipitation with ultrafiltration of the same
serum.
Figure 2.4 provides cLC-MS results for equal quantity protein injections (1 μg) of
post ACN-precipitated serum (panel A) with the filtrate obtained after a 30,000 molecular
weight cutoff ultrafiltration (panel B) of the same specimen. The general TIC patterns
for both samples were somewhat similar, except for the broad peak at 38 min in the
ACN-treated specimen. Panel C and D show the averaged mass spectra of species in 9
minutes of eluate (18-27 min) as indicated in panels A and B respectively. Comparison
of panels C and D, shows that most of the peaks present in the ultrafiltrate were also
present in the ACN-precipitated serum, but the ACN-treated specimen contained many
additional molecular species, some quite abundant, that did not appear in the ultrafiltrate
mass spectrum. This strongly supports the hypothesis that the ACN precipitation method
liberated protein-bound species, making them available for cLC-MS analysis.
In order to confirm that ACN precipitation does indeed release and allow for
analysis of more small proteins and peptides attached to serum albumin and other carrier
proteins, additional experiments were carried out. The first of these involved the
treatment of the large, retained proteins, present after ultrafiltration, with ACN to release
potentially bound species. Figure 2.5 provides typical results from one set of
experiments. In this approach the retentate obtained after a 30,000 molecular weight
cutoff ultrafiltration of serum was explored by cLC-MS. The TIC of retentate prior to
ACN precipitation (panel A) and after ACN precipitation (panel B) are shown. Panel C
shows the averaged mass spectra overlay for MS data collected from 25 to 26 minute

35

elution (as indicated in panels A and B). The retentate prior to ACN precipitation is
shown in blue and the ACN-precipitated retentate is shown in red. As predicted, the
retentate prior to ACN precipitation has a TIC spectrum very similar to that of unfiltered
serum prior to ACN precipitation, and the mass spectrum is dominated by large
molecular weight proteins. Prior ultrafiltration would have effectively removed unbound
small proteins and peptides from the retentate. The appearance then of addition low
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Figure 2.5. Examination of 30K NMW retentate before and after acetonitrile precipitation.
Total ion chromatograms of 1 µg of ultrafiltration retentate prior to ACN precipitation (A) and
retentate after ACN precipitation (B) are shown. C) The averaged mass spectra overlay for
species present in eluate from 25 to 26 min of the cLC separation step are shown. Retentate prior
to ACN precipitation is shown in blue, ACN-precipitated retentate is shown in red. The presence
of the high abundance proteins masked the information rich presence of small peptides.

molecular weight species after ACN precipitation then would evidence dissociation of
bound small proteins and peptides from carrier proteins. This is strikingly evident in
panel C which shows dramatically increased numbers of small molecular weight proteins
and peptides after ACN treatment of the retentate and confirms that this approach makes

36

available many more small, low-abundance proteins and peptides for proteomic analysis.
When these results were extended to a longer time region of the cLC chromatogram,
similar results were obtained (data not shown).
An additional approach is summarized in Figure 2.6 which compares the mass
spectra of ACN-precipitated retentate with the untreated filtrate obtained after
ultrafiltration of a single serum. Panels A and B show the TIC of the ACN-precipitated
retentate and the filtrate respectively. Panel C displays the averaged mass spectra overlay
of 9 minutes of eluate (18-27 min) of the ACN-precipitated retentate (blue) and the
filtrate (red). This overlay shows that ACN treatment produced many additional
molecular species. Interestingly, while both procedures yield small proteins and peptides,
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Figure 2.6. Comparison of ACN-precipitated retentate and filtrate. Total ion
chromatograms of 1 µg of ACN-precipitated retentate (A) and 1 µg of filtrate (B) from 30 K
NMW ultrafiltration are shown. C) The averaged mass spectral overlay for 18 to 27 min of
the cLC chromatogram is presented. ACN-precipitated retentate is shown in blue; filtrate is
shown in red. D) An expanded region (550 to 700 m/z) of Panel C is shown.
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the MS spectrum from the ACN precipitate differed significantly from that of the filtrate,
indicating that two subsets of small proteins and peptides exist and that those in the
ACN-precipitated retentate were not representative of those that routinely passed through
the filter.

Reproducibility
Not only is reproducibility in the precipitation step important, but reproducibility
through the entire cLC-MS analysis is necessary for useful diagnostic applications of
serum proteomics. The reproducibility of this method was tested. The comprehensive
approach of ACN treatment with cLC-MS analysis was carried out on serum specimens
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Figure 2.7. Reproducibility of LCMS day to day. Total ion chromatograms of ACNprecipitated serum of 2 different healthy subjects are shown. A) A TIC of subject 1 serum
(blue), prepared and run on day 1 is shown. B) A TIC of subject 2 serum (red), prepared
and run on day 2 is shown. C) An expanded mass spectral overlay (500-600 m/z) with
inlay expanded to 550-560 m/z of both patients from a 1 min cLC window that had been
calibrated for variations in elution time is shown (blue 25.4-26.4 min, red 24.8-25.8 min).
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Figure 2.8. Reproducibility of LCMS with variable sample handling. A) An overlay of
the TIC of ACN-precipitated serum thawed just prior to analysis (blue) with the TIC of serum
left at room temperature overnight (red) is shown. B) An overlay of the averaged mass
spectrum for cLC elution time of 26-27 min of the ACN-precipitated fresh serum (blue) with
the averaged mass spectrum (same retention time) of the room temperature incubated serum
(red) is provided. The inlay in panel B shows an expanded mass spectrum (1000 to 1100
m/z). Even with delayed handling of the serum, the mass spectra of the samples match closely
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from a healthy patient, prepared and run on the same day. In addition comprehensive
analysis of specimens from healthy patients prepared and run on different days was
assessed.
Mass spectra obtained from different serum specimens from the same patient
prepared and run on the same day were virtually indistinguishable (Data not shown).
Mass spectra obtained from different specimens from different healthy subjects
prepared and run on different days were also remarkably similar after normalization of
elution times (Figure 2.7).
The sensitivity of the results of our approach to variation in specimen handling
was also explored (See Figure 2.8). The panel on the left (A) displays an overlay of the
TIC of ACN-precipitated serum thawed just prior to use (blue) compared with the same
specimen left at room temperature overnight (red). The panel on the right (B) shows the
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Figure 2.9: Variability of LCMS from one individual to another. The same retention time
and m/z ranges were selected from cLC runs of a serum specimen of patient A (normal) and
patient B (case). As shown, the variations in the make up of the serum from individual to
individual can be detected. These differences represent a potential source of serum
biomarkers.

averaged mass spectra overlay of molecular species in one minute of cLC eluate (26-27
min) of the same freshly processed serum (blue) and serum processed after 24 hr at room

40

temperature (red). Despite the delay, the mass spectra matched closely with modest
changes.

Application of Method
As proof of principle of this approach, we applied this method to individuals
representing two differing clinical states. Figure 2.9 shows a narrow region of the mass
spectra (645-655 m/z) obtained after ACN treatment and cLC separation. A restricted
region of the cLC chromatogram for each specimen was selected and an averaged mass
spectrum developed for each. Panel A represents analysis of a specimen from a pregnant
woman with an uncomplicated pregnancy. Panel B displays the results of a specimen
from a pregnant woman of comparable gestational age who had preeclampsia, a severe
complication of pregnancy. There was an additional molecular species at m/z = 648.3 in
the preeclamptic specimen. This is one of several differences found. It is premature to
know if the difference is consistently seen other preeclamptic patients. Nevertheless, it
points out the very real potential of identifying differences between patient populations
that might allow for the accurate diagnosis or prediction of disease, or even the eventual
identification of mechanistic candidates.

Summary
In order to use the information-rich proteomic analysis of serum in a diagnostic
manner, it is essential that the method used to prepare the sample provide reproducible
results. The new method of acetonitrile precipitation described here adequately and
reproducibly precipitates the non-informative, abundant, high molecular weight proteins.
Moreover, this approach increases the number of low molecular weight species that can
be analyzed by cLC-MS. We demonstrate importantly, that the new method of
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acetonitrile precipitation disrupts binding of small proteins and peptides from the large
carrier proteins, providing a larger set of low molecular weight species for analysis. Most
regulatory molecules have been shown to be small proteins and peptides and to be protein
bound in serum; hence the possibility of developing a diagnostic pattern and identifying
potential mediators of disease is increased using this approach. The combination of
protein precipitation coupled with cLC-MS appears capable of meaningful evaluation of
a substantial portion of the serum proteome.
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Part II – Systematic Internal Standard Selection for Capillary
Liquid Chromatography-Mass Spectrometry Time Normalization
to Facilitate Serum Proteomics
Abstract
Because blood interacts with almost all tissues of the body, it is likely that
changes in the overall health of an organism will be reflected in the quantities of specific
serum peptides and proteins, making them biomarkers. Due to the complexity of serum,
pre-analytical sample simplification and separation are needed prior to mass
spectrometric analysis. Use of a reverse-phase capillary column coupled to a mass
spectrometer allows for separation and analysis of serum as part of efforts to discover
biomarkers. Even after sample simplification by organic solvent precipitation, data files
for a single sample typically exceed 1 gigabyte, making it difficult to analyze serum MS
profiles with currently available software. However, with adequate safeguards, it appears
possible to find differences in peak intensities between clinical comparison groups
visually. To facilitate this, an approach was developed where the elution profile was
divided into 2 min intervals in which MS data were averaged. This required that
molecular species had defined, reproducible elution times. Peaks generally had
chromatographic elution peak widths of 1-1.5 minutes. Given cLCMS variation,
misalignment of elution times of individual peaks occurred often. Hence, internal time
controls were identified within each window and used for elution time normalization.
The first has been identified as fibrinopeptide A. These species allowed for peak
alignment across samples improving biomarker discovery.
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Introduction
Medical diagnosis has benefited from the measurement of serum molecules that
are present in lesser or greater abundance in individuals having a specific disease. It is
anticipated that additional biomarkers could provide even more accurate diagnosis,
including sub-classification of disease, staging of disease progression or even providing
risk assessment as part of medical evaluation. If one could achieve a broad survey of
biomolecules altered by a given disease, it may be possible to define molecules that
actually participate in the disease mechanism and are consequently potential drug targets.
Finding such markers then is of significant medical interest. Mass spectrometry (MS) has
been gaining popularity as a means of searching for novel biomarkers in readily available
bodily fluids such as serum, plasma (Hu 2006, Meng 2007, Drake 2007), urine (Mischak
2007), ocular fluids (Grus 2007, Wu 2007), and nipple aspirate fluid (Ruhlen 2007).
Liquid chromatography coupled to mass spectrometry (cLC-MS) has been favored over
other techniques in the search for new biomarkers in our lab due to its ability to provide a
more comprehensive assessment of the peptides and small proteins present in complex
samples than is possible with most other MS methods. This very ability to study
hundreds to thousands of molecular ions in a single sample also generates large amounts
of data, and so poses a major challenge to the use of such methods in finding new
biomarkers due to increased complexity of data analysis. For example, a single cLC-MS
run of a single serum sample typically produces an MS spectral data file that can reach
one gigabyte or greater in size with 4000-5000 observable peaks. As one considers
comparisons of clinical groups, each represented by dozens of specimens, the problem is
compounded. One major challenge is having a straightforward way of addressing day-to-
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day or even run-to-run chromatographic variability so as to then allow direct comparisons
of the spectra of samples run at different times.
Serum is an ideal medium in which to search for new biomarkers because it
interfaces with the vast majority of cells in the body and so likely contains the imprint of
diseased cells in the form of cell specific proteins and peptides, alterations in small
signaling molecules, increased protein fragments, etc. (Zhang 2007) Also, because it is
routinely collected at doctor visits, it is considered to be a minimally invasive specimen,
and one that could be obtained repeatedly as part of prospective studies. Several groups
have studied serum and plasma with the goal of proteomic biomarker discovery for the
diagnosis of various cancers and other diseases. A recent review provides a good
overview of putative biomarkers for human cancer discovered by serum proteome
analysis. (Li 2002) Serum, though easily acquired and well suited for biomarker
discovery, presents challenges. For example, serum contains tens of thousands of
different polypeptides ranging in size from a few to several hundred amino acids and
spanning nine orders of magnitude in concentration. (Adkins 2002, Anderson 2002) The
22 most abundant proteins in serum account for 99% of the total protein in serum. (Meng
2007)
Due to the extreme complexity of the protein complement found in serum, made
even more complicated by variable post-translational modifications, including protein
glycolsylations, a separation step is required. Capillary column chromatography allows
for the direct interfacing of columns with the mass spectrometer while providing a robust
fractionation step. However, whole serum can easily foul capillary columns. Hence,
removal of abundant, but typically uninformative, proteins is desirable. Additionally, MS
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instrumentation typically has a detection dynamic range of only two orders of magnitude,
so the observation of low abundance species is difficult without removal of the highlyabundant serum proteins. High-abundance species can cause signal suppression that
blocks detection of lower abundance species. For all of these reasons, pre-analytical
sample simplification of serum is needed prior to MS analysis.
A common method of simplifying a serum sample involves precipitating the
large, high abundance proteins out of solution using an organic solvent. In addition to
removing large proteins, this treatment has the added benefit of denaturing proteins
acting as carriers, liberating smaller bound molecules. Because small proteins and
peptides will be filtered from blood by the kidney (Adkins 2002, Liotta 2003, Petricoin
2002 Clinical), small molecules that the body deems important enough to keep around are
bound to larger proteins to prevent their loss, giving them a longer half-life within the
blood stream. Consequently, denaturing serum substantially increases the number of
small proteins and peptides available for MS assay. However, many published methods
of serum simplification remove these larger molecules without taking steps to ensure that
any smaller proteins bound to them are released. It is in this low-molecular weight lowabundance fraction of the human serum proteome that many biomarkers are likely to be
found (Meng 2007, Liotta 2003). Even with over 99% of total protein removed from the
serum samples via organic solvent precipitation, there remain in solution thousands of
molecular species. We have developed a cLC-MS proteomics approach to search for
potential biomarkers in large and complex data sets produced from analysis of human
serum samples. Protein removal is followed by a reverse-phase capillary column step to
help to separate the sample over time, reduce signal-suppression and allow us to get a
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better overall picture of the state of the fraction of the low-molecular weight proteome of
the patient that we are focusing on.
When such a sample is analyzed using cLC-MS, a large and very complex three
dimensional data set is produced. Currently available software has been very good at
three dimensional comparisons of simple data sets, but has proven inadequate when
working with the large, complex data sets produced using our methods. Lack of current
software capable of analyzing these data sets has led to searching for peptides of interest
within our data manually.
The complex nature and sensitivity of the LC instrumentation employed, as well
as slight variations in the hand-packed columns used caused the elution times of peptides
and proteins to vary from day-to-day and run-to-run. Although the start time of the
overall elution profile may vary from sample to sample, the elution order and the relative
elution times of molecular species within a single sample run stay generally constant.
Because most chromatographic peaks require 1-2 min to elute completely and in an effort
to reduce the size of data sets and keep peak number manageable, we defined 2 minute
elution windows along the chromatogram to allow comparison across several specimens
in a sample set or between sample sets. Within each window we located a central peak,
typically a peptide, found in all specimens that could be used as a reference allowing for
time alignment. Once aligned, the spectra can be overlaid and searched for quantitative
differences between comparison groups. Any differences discovered can then be further
studied as possible biomarkers.

Materials and Methods
All reagents were purchased from Sigma (St. Louis, MO) and used without
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further purification.

Sample Collection
Blood was obtained by antecubital venipuncture at the BYU Student Health
Center from a healthy female volunteer. Blood was allowed to clot for 30 minutes at
room temperature, and after centrifugation at 3,500 rpm for 15 min, serum was collected,
aliquoted and frozen and maintained at -80°C until further processing.

Acetonitrile Precipitation
This method has been described in detail in a previous paper. (Merrell 2004)
Briefly, two volumes of HPLC grade acetonitrile (400 μl) were added to 200 μl serum,
vortexed vigorously for 5 sec and allowed to stand at room temperature for 30 min.
Samples were then spun for 10 min at 12,000 rpm in a centrifuge at room temperature.
An aliquot of supernatant (550 μl) was then transferred to a new microcentrifuge tube to
which was added 300 μl HPLC grade water, the two mixed, and the mixture then
lyophilized to ~200 μl in a vacuum centrifuge (LABCONCO CentriVap Concentrator) to
remove any acetonitrile. Supernatant protein concentration was determined using a BioRad microtiter plate protein assay (BioRad, Hercules, CA) according to manufacturer
instructions. An aliquot containing 4 μg protein was transferred to a new microcentrifuge
tube and lyophilized to a volume < 20 μl. The sample was brought to 20 μl with HPLC
water to which was added 20 μl 88% formic acid and the sample was mixed vigorously.

cLC-MS Analysis
Capillary liquid chromatography (cLC) to fractionate or separate peptides and
proteins was performed using a 15 cm x 250 um i.d. capillary column, packed in-house
using POROS R1 reversed-phase media (Applied Biosystems, Framingham MA).
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Elution was accomplished employing a 2.2%/min gradient from 0% organic to an organic
concentration of 60% acetonitrile in 0.1% formic acid, followed by a 3.5%/min gradient
up to a concentration of 95% organic phase. In-line chromatographic separation used an
LC Packings Ultimate Capillary HPLC pump system with a FamOS autosampler (Dionex
Corp) controlled by the mass spectrometer software (Analyst, Applied Biosystems). The
cLC was coupled directly to the MS. Effluent from the capillary column was directed
into a QSTAR Pulsar i quadrupole orthogonal time-of-flight mass spectrometer through
an IonSpray source (Applied Biosystems). Data was collected for m/z 500 to 2500 over
the entire chromatogram (55 min total including void volume, elution and
reequilibration). Data collection, processing and preliminary formatting were
accomplished using the Analyst QS software package with BioAnalyst add-ons (Applied
Biosystems).

cLC-MS/MS Analysis
A specimen containing 0.5 μg of total protein was loaded onto the column and a
MS run was performed to determine the exact elution time of the peptide of interest. A
MS/MS run was performed on the same amount of protein with collection of MultiChannel Acquisition (MCA) fragmentation data at a set collision energy of 30 for the two
min time span in which the peptide of interest eluted. The fragmentation spectra were
sent to MASCOT for identification. The first peptide used for elution time normalization
had a mass of 1464.6 and was successfully identified as fibrinopeptide A.

Selection of Reference Peaks for Chromatographic Normalization
Using 2-D and 3-D visualizations of complete serum runs, multiple peaks that
eluted at ~2 min intervals were selected as possible reference peaks. The Extract Ion
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Chromatogram (XIC) function was used to check the chromatographic elution profile of a
small m/z range that included the m/z of the possible reference peaks. To be further
considered as possible reference peaks, chromatographic elution profiles of the selected
peaks had to be relatively narrow (< 2 min), well shaped (close to Gaussian in shape), and
having elution profiles that were well resolved and distinguishable from those of other
molecular species of similar m/z. Those peaks that best met these criteria were further
investigated in serum runs from various individuals prepared and run on different days.
Ten peaks that eluted at ~2 min intervals and were ubiquitously present in all serum
samples were selected as markers.

Normalization of Elution Times
Differences in elution time were corrected by aligning the central reference peaks.
In practice this was accomplished by generating an averaged mass spectrum of the
interval represented by exactly1.00 min before and after a given reference peak,
irrespective of its actual chromatographic elution time. Comparable mass spectra were
generated for each specimen in the comparison groups for each of the 10 internal time
controls. To evaluate the utility of the approach 2 peaks (one running before and running
after the reference peak for first window) were monitored in several samples of a single
pool of normal serum. There were several aliquots of this pool assayed on the same day
(n=10 on two separate occasions) and several aliquots (n=17) of the pool assayed over
several days. Initially, the actual elution time of each test peak was obtained from the
XIC plot of each of 27 runs, 10 run on the same day and this done twice and 17 on other
days. As a quantitative indication of the effectiveness of time normalization we looked at
variability around two means. The first mean was the mean elution times of these two
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peaks as established for the whole set, as well as for same day and day-to-day runs. Then
the mean elution time variance was calculated as was the absolute difference between
that mean and an individual elution time for each analysis. These differences between
actual value and mean value were considered the measure of variability and were
compared with normalized data. To determine variability of the time normalized data
first the time difference between the internal control and each of the two test peaks for
each sample was calculated. This is termed the offset time. These offset times in turn
were averaged and the absolute difference between a given offset time and the mean was
calculated. The variability in this difference was then considered to be the variability
after normalization and was compared to the un-normalized data statistically.

Statistical Analysis
Numerical data are presented as the mean + SE of the mean. Comparisons of
variability were made by compiling the individual elution times for test peaks,
determining the mean and finding the absolute difference between an individual elution
time and the mean. As described about the variability in the difference between the mean
elution time and the actual individual elution times was then compared to normalized
data. For the normalized data the same central internal control was used, the same test
peaks were used and their time difference (offset time) to the internal control was
determined. These values were averaged and the variability in offset times was estimated
by calculating the difference between the mean offset time and each individual offset
time. The two sets of time variability were compared by Student’s t-test. A p-value
<0.05 was considered significant.
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Figure 2.10. Selection of peptide elution standards. Labeled peaks within the
chromatograms shown represent the XIC elution profiles of the 10 molecular species chosen as
standards.

Results
In an effort to correct for differences in day-to-day and even run-to-run
chromatographic variation between samples an approach was developed using internal
controls. To do this 10 molecular ion peaks were selected that were present in all human
serum samples and that eluted at approximate 2 minute intervals throughout the elution
period. These were used for time normalization of serum samples run by cLC-MS
(Figure 2.10) It was unimportant as to whether the peaks selected were in any particular
charge state, whether they represented the monoisotopic peak within a charge envelope,
or were even peptidic in nature. (Table 2.2) Provided that these internal control species
52

had a recognizable m/z value, eluted at a point of interest, were consistently found in all
specimens and were chromatographically well behaved, their structure or chemical
identities were not necessary for them to be useful as a reference. In reality, the identities
of these control species are unlikely to be interesting in the context of biomarker
discovery, given their abundant and uniform nature.
Marker
#
1
2
3
4
5
6
7
8
9
10

m/z of
reference peak
733.3
721.3
1006.0
1013.5
547.3
547.3
1047.7
637.3
781.5
1620.2

Charge
State
+2
+2
+2
+5
+1
+1
+1
+1
+1
+1

Is
monoisotopic
Yes
No
Yes
Yes
Yes
No
Yes
Yes
No
Yes

Relative Elution
Time (min)
0
2.2
3.7
6.3
8.7
10.9
12.8
17.3
19.8
22.1

XIC
Window
733-734
721-722
1006-1007
1013-1014
547-548
547-548
1047-1048
637-638
781-782
1620-1621

Table 2.2. The m/z value of the selected ten reference peaks is shown along with their
charge state, position in the isotope envelope, average elution time (n=160) relative to that
of the first standard, and the values used for each XIC window.
Nevertheless, once the 10 alignment controls were chosen as markers, attempts were
made to sequence those that were peptides using MS/MS. These efforts provided partial
but insufficient amino acid sequence data to allow identification of all but one of the
standards due to their large size (m/z 1013.5), the species being non-peptidic in nature
(m/z 547.3), fragmentation being poor (m/z 1006.0), fragmentation producing only very
small fragments (m/z 721.3), or for other reasons. To date only the first standard (m/z
733.3 where z = 2) has been successfully identified. The peptide was Fibrinopeptide A
(Figure 2.11).
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Figure 2.11. Identification of the first peptide standard. The first serum standard has been
identified as Fibrinopeptide A using cLC-MS/MS. The fragmentation spectra and resultant
identification made by submitting the data to the MASCOT search engine are shown above.

Time windows (2.0 min) centered on each of the XIC elution times of the ten standards
allowed for time normalization. This in turn allowed for the overlay of up to 16 different
spectra averaged over that 2 min window. As a demonstration of the utility of this
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approach several separated runs of a single human serum (limiting biologic variability)
were carried out. Two peaks in the first time window were selected having m/z ratios of
675.4 and 1050.5 respectively. The actual elution time for each of these two species was
determined for 37 separate samplings. Then the relevant windows were aligned and the
time differences between runs were calculated from the reference peak (m/z 733.4). This
brought about a marked and significant reduction in the variability of the time
measurement (Table 2.3). Specimens run on the same column, same day were more
consistent in terms of the actual elution times than those run on separate days.
Nevertheless, the internal time controls allowed for a significant reduction in variation in
either case (Table 2.3).

Discussion
Ten internal serum peptides were selected as standards for cLC-MS time
normalization. Many more peaks met the criteria needed to be considered as internal
standards. Those chosen were selected in part for their location within the cLC
chromatogram and their convenience in use. It was unimportant as to whether the peaks
selected were in any particular charge state, whether they represented the monoisotopic
peak within a charge envelope, or were even peptidic in nature.
Of those finally selected most were monoisotopic, but a few were not. The MS
instrumentation is sensitive enough to detect sub-dalton differences in mass. Due to the
natural abundance of 13C, any molecule containing carbon atoms has a chance of one or
more of those carbons being 13C instead of the more common 12C. Molecules detected
using MS typically show up as a series of peaks, representing the mass change that results
from addition of one, two, or more neutrons as a result of incorporation of 13C molecules.
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Data set

No normalization

Normalized

Same day set 1 (n=10)

From mean + SD

From mean + SD

P

Peak 1

0.090 + 0.048 min

0.010 + 0.014 min

0.00029

Peak 2

0.060 + 0.040 min

0.010 + 0.012 min

0.0016

Same day set 2 (n=10)

From mean + SD

From mean + SD

P

Peak 1

0.110 + 0.092 min

0.020 + 0.017 min

0.0070

Peak 2

0.080 + 0.065 min

0.010 + 0.013 min

0.0044

From mean + SD

From mean + SD

P

Peak 1

1.06 + 0.88 min

0.15 + 0.075 min

0.000175

Peak 2

0.90 + 0.84 min

0.23 + 0.152 min

0.003

From mean + SD

From mean + SD

P

Peak 1

0.78 + 0.65 min

0.09 + 0.07 min

0.002

Peak 2

0.80 + 0.57 min

0.18 + 0.11 min

0.003

Day-to-day set 1 (n=17)

All determinations (n=37)

Table 2.3. Comparison of variability in raw elution times without time alignment with the
variability in offset times after time alignment for two peaks. Peak 1 = m/z 675.4, peak 2 = m/z
1050.5. Both peaks were found in the first elution window which also contained the central time
alignment peak (m/z 733.4).

The peak that represents the molecule with all 12C and no 13C is called the monoisotopic
peak. If a monoisotopic molecular species did not conform to the selection criteria, a
species within the 13C isotope envelope that did conform to the selection criteria was
chosen instead. Use of these internal peaks as controls produced consistent elution time
alignment across all sample runs and this in turn allowed for visual inspection of spectral
overlays in the search for potential biomarkers. It is worth noting that a highly specific
and useful proteomic control does not require knowledge of its actual composition
provided it has a consistent and identifiable mass, is sufficiently abundant and resolved
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from other species. Attempts at identification of the ten time standards have found that
some of the current markers are not peptides, but they have still proven useful in this
approach. Likewise, a highly specific proteomics pattern can be useful in the prediction
or diagnosis of a disease in the absence of the complete knowledge of the chemical
composition of the individual constituents in that pattern, although such information may
prove useful in the understanding of the disease process.
Using this approach, we demonstrated that normalizing elution times in the
straight forward manner described here markedly decreased timing misalignment for any
specific peak across multiple analyses of the same specimen. This was evident as a
marked decrease in variability of elution time relative to the standard versus the actual
cLC elution times. The impact of this is potentially large. For intraassay variability the
average deviation from the mean was ~0.1 min without normalization but some
specimens differed by as much as 0.3 min on either side. Considering the 2 standard
deviations, this creates a range of values that varies somewhat over 0.3 min. Even so,
this is reduced to ~0.01-0.02 min with a range of values that spans 0.04 min after
normalization. The intraassay variability is even more impressive. There the mean
elution time variability was ~ 1 min with a range (+ 2 SD) of ~ 3.5 min. After time
alignment the mean time variability was ~ 0.2 min with a range of 0.4 min. Given that
our elution windows are 2.0 min, it is entirely possible that a given peak might be
inadvertently omitted if time normalization were not employed.
The significance of these results is primarily in the context of biomarker
discovery. With advances in mass spectrometric technology has come the possibility of
assessment of biological molecules, even in the serum. Likewise, with more innovative
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proteomic approaches there have been and will continue to be dramatic increases in both
the size and complexity of the data sets accessed by the instrumentation. The need for
additional biomarkers for medical diagnosis and clinical risk assessment of many
diseases is widely acknowledged. Analysis of these data is becoming increasingly

Figure 2.12. Spectra overlay for biomarker discovery. The XIC elution time for one of the
standards was recorded for each of 8 male (blue) and 8 female (red) sample runs. A two-minute
window was centered around this time and the resultant spectra were overlaid. The resultant
spectral overlay can then be searched for biomarker candidates. Notice that in this case the
intensity of the blue peaks was greater than the red for most of the spectral overlay, but the
pattern suddenly changed for the peaks in the middle. Such differences could be recorded and the
peaks would be further investigated as possible biomarkers.

difficult and advances in software capable of analyzing these large and complex data sets
has lagged behind advances in instrumentation. cLC-MS produces such massive data
sets that current software cannot manage such file size and it is necessary to parse the
elution interval into discrete reproducible windows. While this approach to data analysis
reduces the file size and makes more manageable the absolute number of peaks to be
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considered, it creates the possibility that peaks of interest actually overlap two windows
or to a substantial degree fall outside the relevant time window. If time is misaligned,
then more or less of a given molecular species will be included in the analyzed window
potentially giving rise to differences in peak heights and areas due to location within the
window, which is related to the uncertainties in elution time variability rather than
clinically related differences. When spectra from two clinical groups are overlaid, our
experience has clearly shown that the eye is very good at locating peaks that are
quantitatively different. (Figure 2.12) However, to insure that the quantitative differences
are due to biological change and not to the partial inclusion or exclusion of a peak due to
chromatographic time differences, the use of this time alignment approach involving
endogenous internal controls dramatically reduces this problem and allows for successful
identification of peaks that differ between clinical groups. While this approach is
somewhat laborious and time intensive, use of this method has led to the discovery of
several statistically significant novel clinical biomarkers that are under active
investigation.
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Part III – A comprehensive serum proteomic approach capable
of monitoring the low molecular weight proteome with
sequencing of intermediate to large peptides.
Summary
The low-abundance, low molecular weight serum proteome has high potential for
new biomarker discovery using mass spectrometry (MS). Because the serum proteome is
large and complex, defining quantitative differences for a molecular species between
comparison groups requires an approach with robust separation capability, high
sensitivity, as well as high mass resolution. Capillary liquid chromatography (cLC)-MS
provides both the necessary separation and the sensitivity to observe thousands of lowabundance peptides. Subsequent identification of potential serum peptide biomarkers
observed using cLC-MS can in principle be accomplished by cLC-MS/MS without
further sample preparation or additional instrumentation. In this report a novel cLCMS/MS method for peptide sequencing is validated that surpasses previously reported
size limits for amino acid sequencing accomplished by fragmentation studies.
As a demonstration of the approach, two low-abundance peptides with a mass of
~ 4000–5000 Da were selected for MS/MS identification. The multi-channel analyzer
(MCA) was used in a novel way that allowed for summation of 120 fragmentation spectra
per each of multiple customized collision energies, providing more thorough
fragmentation coverage of the peptide with improved signal to noise. The peak list from
this composite analysis was submitted to Mascot for identification. The index 4279 Da
and 5061 Da peptides were successfully sequenced and identified from a single sample
using cLC-MS followed by cLC-MS/MS on a single platform. The peptides were a 39
amino acid immunoglobulin G heavy chain variable region fragment and a 47 amino acid
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fibrin alpha isoform C-terminal fragment. The methods described here provide the
ability on a single platform to both survey thousands of serum molecules and couple that
with a dramatic enhancement in the peptide sequencing capabilities of cLC-MS/MS ,
providing an effective technique for serum biomarker discovery.

Introduction
Serum is a promising source from which to identify novel biomarkers. Blood is
intimate with most regions of the body, and it is likely that changes accompanying
abnormal or disease states could be reflected in the low molecular weight complement of
the blood. In addition, because serum can be collected in a minimally invasive way, it is
more easily and acceptably available for analysis than other tissues. However, serum is
complex and several challenges are involved in using it in the search for biomarkers.
These challenges fall generally into three categories: the complexity of the specimens
themselves, the limits of instrumentation, and the analysis of the data.
Because no serum proteomic method is able to measure all peptides and proteins,
any serum proteomic approach requires the rational selection of which proteome crosssection will be assessed. When working with serum, the removal of bulk proteins from
serum can be important for several reasons: Ninety-nine percent of the protein in serum is
comprised of only 22 abundant proteins. (Anderson 2002) The concentration of the least
abundant protein in serum differs from that of the most abundant by over 10 orders of
magnitude. (Anderson 2002, Jacobs 2005) Additionally, capillary liquid chromatography
separations of whole serum are problematic. Consequently, depleting the sample of bulk
proteins is vital to observing the thousands of less abundant proteins and peptides.
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Furthermore, the fraction of the serum proteome that has the highest potential for
new biomarker discovery has been suggested to be the low-abundance, often lower
molecular weight (LMW) proteins and peptides. (Liotta 2003) Because many regulatory
peptides and proteins are bound to large carrier proteins in the blood, to study these
compounds’ role in health and disease, they need to be displaced from their larger carrier
proteins.
All of these considerations make organic solvent precipitation of larger, serum
proteins—including the abundant and less informative proteins—with its added ability to
liberate bound species an attractive first step in accessing this important serum proteome
subset. (Merrell 2004)
The complexity of serum (even of protein-depleted samples) places high demands
on the analytical approach, especially the instrumentation. The four most common MS
platforms used for proteomic analysis are matrix-assisted laser desorption/ionization
mass spectrometry (MALDI) (Hortin 2006), Fourier-transform ion cyclotron resonance
(FTICR) (Bogdanov 2005), surface-enhanced laser desorption/ionization (SELDI) (Li
2002, Diamandis 2004), and capillary liquid chromatography coupled to online
electospray-ionization mass spectrometry (cLCMS) (Merrell 2004, Koomen 2005). Of
these, only cLCMS provides a sufficiently robust separation capability to survey the
thousands of peptides and LMW proteins present.
Once quantitative differences can be documented using serum proteomics, a
protein or peptide is ideally sequenced prior to use as a potential biomarker. cLCMS
facilitates this identification because of the seamless shift from cLCMS in the discovery
stage to cLCMS/MS in the identification stage. Identification by cLCMS/MS has been
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achieved by either collisionally-induced dissociation (CID) or electron capture
dissociation (ECD). In CID, repeated collisions of the peptide of interest with inert gas
confer energy to the molecule, causing fragmentation at the weakest peptide bond. ECD
does not involve a transfer of energy and so the resulting fragmentation does not depend
on bond strength. (McLafferty 2001) Because of the differing mechanisms of
fragmentation, these techniques are thought of as complementary, but a recent
comparison of the two methods showed only a 12% overlap in identification between
CID and ECD. Molecules with charge states above +2 were more effectively fragmented
with ECD, while those with charge states of +1 and +2 were more effectively fragmented
with CID. (Good 2007) An ideal method would utilize both of these identification
strategies. Unfortunately, instruments capable of ECD are costly and relatively
uncommon compared with instruments that use CID as their sole method of
fragmentation. As proteins get larger, the efficiency of the CID process decreases with a
smaller proportion of the backbone bonds cleaved. (Loo 1988, Horn 2000) Some peptide
bonds are more labile than others, and thus more likely to be fragmented. (Zubarev 2008)
As a result, not all fragments will be present at equal yield. Despite these complications,
we show here that it is still possible to get useful fragmentation data from large, multiplycharged peptides using CID.
The approach described can overcome the significant challenges of CID-induced
cLCMS/MS of peptides and LMW proteins including: 1) low signal-to-noise of daughter
ions produced by fragmentation of peptides larger than 20 amino acids in length, 2) low
dwell time at specific collision energies (CE) because of the instrument typically
imposing rolling collision energies, and 3) the high complexity of the fragmentation data

63

produced and submitted to database searches. As proof of principle, the comprehensive
proteomics approach described here has been used to sequence two low-abundance index
peptides, both having charge states of +6, and 39 and 47 amino acids in length
respectively. These were not sequenced using the standard automated approach. The
customized approach explained here then offers a way to extend the capability of cLCMS
coupled with cLCMS/MS as a tool for peptide biomarker discovery.

Experimental Procedures
Sample Collection
Blood samples were obtained at the Brigham Young University Student Health
Center from a healthy female volunteer, collected into serum separator tubes and
processed after clotting by centrifugation to produce serum. The serum sample was
aliquotted, frozen, and stored at -80° C until use.

Acetonitrile Precipitation
High molecular weight, high-abundance proteins were precipitated out of solution
using a previously published method (Merrell 2004), modified as noted below. Briefly,
two volumes of HPLC grade acetonitrile (400 μl) were added to 200 μl serum, the sample
was vortexed vigorously for 5 sec and allowed to stand at room temperature for 30 min.
Samples were then centrifuged for 10 min at 13,400 x g at room temperature. An aliquot
of the supernatant (~550 μl) was then transferred to a microcentrifuge tube containing
300 μl HPLC grade water. The sample was vortexed briefly to mix and then lyophilized
to ~200 μl in a vacuum centrifuge (Labconco CentriVap Concentrator, Labconco
Corporation, Kansas City, MO). Water added prior to lyophilization aided in the
complete removal of acetonitrile from the solution and is the only change from the
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previously published method. This step was necessary because acetonitrile is
incompatible with the assay used to determine protein concentration and complicates
sample loading onto the reversed-phase cLC column. Supernatant protein concentration
was determined using a Bio-Rad microtiter plate protein assay performed according to
manufacturer instructions (Bio-Rad, Hercules, CA). An aliquot of the same supernatant
containing 4 μg of total protein was transferred to a new microcentrifuge tube and
lyophilized to a volume less than 20 μl. Lyophilized samples were brought to 20 μl with
HPLC water and acidified by addition of 20 μl 88% formic acid. The excess, unacidified
supernatant was stored at –20° C for subsequent LC/MS analysis.

LC Separation
Protein-depleted, acidified serum samples (40 μl) were placed into a FAMOS
autosampler 48 well plate (Dionex Corporation, Sunnyvale, CA) kept at 4° C. The
autosampler injected 0.5 μg (5 μl) of each serum sample onto the guard column using
HPLC water acidified with 0.1% formic acid at a flow rate of 40 μl/minute.
Capillary liquid chromatography used an LC Packings UltiMate Capillary HPLC
pump system, with a SWITCHOS switcher and flow splitter, and a FamOS autosampler
(Dionex), controlled by Analyst QS® software supplied with the QSTAR® mass
spectrometer (Applied Biosystems, Foster City, CA).
The cLC columns included a 1 mm (16.2 μl) microbore guard column (Upchurch
Scientific, Oak Harbor, WA) and a 15 cm x 250 um i.d. capillary separation column
assembled in-house. The guard column was dry-packed and the capillary column was
slurry packed using POROS R1 reversed-phase media (Applied Biosystems,
Framingham, MA). Column equilibration and chromatographic separation were
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performed using gradient elution employing an aqueous phase (98% HPLC H2O, 2%
ACN, 0.1% Formic Acid) and an organic phase (2% HPLC H2O, 98% ACN, 0.1%
Formic Acid). Separation was performed beginning with a 3 minute column
equilibration at 95% aqueous solution, followed by a 2.75%/min gradient to 60% organic
phase, which was then increased at a rate of 7% increase/min to a concentration of 95%
organic phase. The gradient was held at 95% organic phase for 4 minutes to elute the
more hydrophobic portion of the sample, then dropped to 5% organic phase to reequilibrate the column. All separations were performed at a flow rate of 5 μl/min.

MS Analysis
Effluent from the capillary column was directed into a QSTAR Pulsar i
quadrupole orthogonal time-of-flight mass spectrometer through an IonSpray source
(Applied Biosystems). Data was collected for m/z 500 to 2500 beginning at 5 and ending
at 40 min elution time. Data collection, processing and preliminary formatting were
accomplished using the Analyst QS software package with BioAnalyst add-ons (Applied
Biosystems).

Peptide Selection
To choose a peptide for cLC-MS/MS identification, the cLC-MS spectrum was
visually inspected for multiply charged peptides with a mass of 4000-5000 Da that were
present in relatively low amounts compared with other molecular species eluting near the
same time. The selected peptides needed to have eluted completely within a two-minute
window and needed to have good chromatographic separation from other molecular
species of similar m/z. The peptides that were chosen for this proof-of-principle study
had masses of 4279.2 Da (m/z 714.2) and 5061.1 Da (m/z 844.6), with relative average
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Figure 2.13.

13

C isotope envelope and relative intensity of serum peptide peaks at m/z
714.2 and m/z 844.6. These peptides had intensities of 2.8 and 1.4 respectively, relatively low
compared to other molecular species that eluted at the same chromatographic time. The low Q1
resolution setting used stabilized the flight paths of molecules within ±2 m/z of the target peak
selected. Thus, though the monoisotopic peaks for these species occurred at m/z 714.2 and m/z
844.6 in their +6 charge states, fragmentation was best achieved by targeting a peak within the
isotope envelope having a higher m/z, in this case m/z 714.5 and m/z 844.9.
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intensities (ion counts) of 2.8 and 1.4 in the +6 charge state when summed over 120
seconds (Figure 2.13).

MS/MS Analysis
Frozen, unacidified supernatant was thawed and an aliquot of 88% formic acid
equal to the volume of sample was added. For each LC-MS/MS run, 0.5-2 μg of the
acidified processed serum supernatant was hand injected onto the column to avoid sample
loss in the injection loop. MS/MS fragmentation data were collected for m/z 70 to 2000
beginning at 17.92 min and ending at 19.92 min for the peak at m/z 844.6 and beginning
at 17.69 min and ending at 19.69 min for the peak at m/z 714.2, these times marking the
chromatographic window where the index peptide eluted as determined from the cLCMS
run (Figure 2.14). Parent ion passage into the collision chamber was done with Q1
resolution set at “LOW” and the multi channel analyzer (MCA) was turned on. As part
of this approach to obtain better sequence coverage of fragmentation patterns, 0.5 μg of
sample was run seven times with collision energies (CE) of 15, 17, 20, 22, 25, 27, and 30
for the 714.2 m/z peak. These values correspond to the amount of the voltage drop (eV)
that accelerates ions through the collision cell. Higher voltages produce greater
acceleration and greater momentum at impact with inert gas (N2) in the collision cell of
the mass spectrometer. Higher values for the CE correspond to higher amounts of
collision energy and smaller daughter ion fragments. The fragmentation of the 844.6 m/z
peak was acquired using 1 μg of sample for each of 3 runs with a CE of 30, 35, and 37
and 2 μg of sample for each of 4 runs with a CE of 25, 27, 40 and 45.
Using the “Overlay” feature of the Analyst software the seven summed MS/MS
spectra that were collected at the different collision energies were overlaid for each
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Figure 2.14. Elution profiles of the index peptides at m/z 844.6 (A) and m/z 714.2 (B).
Total ion chromatogram (TIC) of 0.5 µg of total serum sample (top) and the extract ion
chromatogram (XIC) of the range ± 0.75 m/z units from the peaks of interest (bottom) are
shown. The peptides chosen for this study eluted at 18.92 ± 1.0 min (m/z 844.6) and 18.69 ±
1.0 min (m/z 714.2).
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parent ion. The “Add Data” feature was then used to compile or combine data without
averaging these seven MCA spectra together, giving a single MS/MS spectrum with
fragmentation coverage over much of the sequence of the peptide (Figure 2.15). After
the spectrum was smoothed, the threshold was set at 1.5 and the data was centroided.
The centroided data threshold was set at 3.0 and the data list was exported to Excel.

Figure 2.15 Addition and smoothing of 7 MCA MS/MS fragmentation spectra. Individual
runs at single collision energies had relatively low levels of signal-to-noise (A). The spectra of
several runs of the same specimen at different staged collision energies were overlaid (B) and
then summed (C). The resultant compiled spectrum was then smoothed prior to sequence
analysis (D). This procedure allowed for more comprehensive fragmentation coverage and
increased signal without significantly increasing baseline noise.

The spectrum was visually inspected and compared to the exported data list to
ensure the software had assigned charge states correctly (Figure 2.16). A previous study
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has shown that identification has been improved after deconvolution of the raw data.
(Mujezinovic 2006) After any corrections, we transformed the data list using the
formula: (+1 mass) = m/z value * (charge – (charge – 1)) so all species with charge states
above +2 had a +1 mass listed. Peaks with undefined charges were considered to have +1
charge states. This corrected list was exported from Excel as a tab-delimited text file.

Figure 2.16. Peak charge assignment correction. The data list for the compiled spectrum
was exported to Excel and then visually checked to make sure the software had assigned charge
states correctly. The software was usually accurate for lower charge states, but often had
difficulty correctly assigning higher charge states. The +6 charged molecular species shown had
been labeled as being a +3 species.
Regardless of the charge state of the parent ion, Mascot (www.matrixscience.com) only
searches for matches to +1 and +2 fragments. Converting all fragments with charges of
+3 and above to +1 allows Mascot to match those fragments. The text file was edited to
have the following format: SEARCH=MIS; REPTYPE=Peptide; BEGIN IONS
PEPMASS=844.6 (tab delimited data list (m/z intensity); END IONS. This text file was
saved as a .tmp file, and this file was submitted to a Mascot MS/MS ions search. We
searched the NCBInr database, limiting the search to mammalian sequences. The enzyme
setting was set to ‘none’ with peptide and MS/MS tolerances of ± 1.0 Da, with a +6
peptide charge selected. The data was in Mascot generic format and the instrument used
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was designated as ESI-QUAD-TOF. Comparable amounts of serum were loaded and the
peak of m/z 714.2 was targeted at CE 10, 17, and 25 to compare the intensity difference
of spectra run with the MCA setting turned on and off.

MS/MS Sequence Analyses Performed by Standard IDA, by Customized
Approach without MCA as Compared with the Full Customized Approach.
To better understand the utility of our method the same protein-depleted serum
sample was submitted to the same cLCMS step followed by different MS/MS sequencing
approaches.
In the first of these analyses, 0.5 μg of the protein-depleted sample was introduced
onto the cLC column as described above. Peptide selection and sequencing were
investigated using information-dependent acquisition (IDA). In this mode the instrument
uses a one-second MS survey scan followed by 3, three second CID fragmentations with
a rolling collision energy employed during the fragmentation period. The IDA mode is
programmed to carry out fragmentation of the three most abundant peptides in each of
these scans. The masses of the collision fragments were put on an exclusion list for 180
seconds, which exceeded the typical peak elution time of 60 seconds. The resulting
spectra were submitted to Mascot for identification as outlined above with the charge
setting set to look for matches to +1, +2, and +3 peptides. Peaks not considered by IDA
but of greater abundance than each of the low abundance index peptides studied in their
relevant mass spectra were also numbered as an indication of the IDA method sensitivity.
In order to carry out a more direct comparison of fragmentation methods, one of
the 5 peptides identified when using IDA in the previous experiment was also submitted
to the customized sequencing approach described above but with the MCA turned off as
well as on. Analyses were carried out on 0.5 μg of the same protein-depleted serum
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sample, submitted first to cLCMS to locate the target peptide. The location of the target
peptide was determined. The peak used represented a peptide in a +2 charge state having
an m/z of 733.4. Then the peak was submitted to sequence analysis, collecting 120
MS/MS scans of the target peptide peak at a constant CE of 30, with the MCA both off
and on. The fragmentation data was processed as described above and submitted to
Mascot for possible peptide identification.

Results
Serum Proteomic cLC-MS
Protein-depleted serum was fractionated by gradient, capillary LC as described
above and introduced into a time-of-flight mass detector by electrospray ionization.
Approximately 4000-5000 distinct molecular ions were detectable using this approach.
Based on low peak height, presence of a multiply charged state, being consistently found,
and having amino acid sequence lengths of ~40-50 amino acids, two low abundance
peptides were arbitrarily selected for further MS/MS analysis. The peptides chosen for
this proof-of-principle study had masses of 5061.6 Da (m/z 844.6) and 4279.2 Da (m/z
714.2), with relative intensities (ion counts) less than 3 and 2 in the +6 charge state
(Figure 2.13), which consistently eluted at 18.69 ± 1.0 min and 18.92 ± 1.0 min from the
cLC-MS column using the gradient outlined above (Figure 2.14).

cLC-MS/MS Fragmentation
The amino acid sequences of these peptides were subsequently determined by
cLC-MS/MS. Because the duty cycle of the instrument is such that one spectrum was
taken every second, each two-minute elution window produced 120 total MS/MS spectra.
With the Q1 resolution setting at ‘LOW’, the flight paths of a small range of m/z values
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(±2 m/z) were stabilized through the quadrupole and subjected to collision cell

Figure 2.17. Comparison of fragmentation collected with the MCA feature turned on (A)
and off (B). Without using the MCA feature, the maximum signal level reached 0.30 while the
signal reached a maximum of 65 with the MCA turned on. Peak shape was marked improved,
but signal to noise was only improved two to three fold.
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Figure 2.18. Fragmentation of the peptide, m/z 733.4 at CE 30 collected both with (A) and
without (B) the MCA function turned on. This peptide was one of five identified using the
IDA function for peptide sequencing. It was rerun using our approach for the sake of
comparison. Although the MCA setting increased the intensity by over 500 times, both
approaches also identified the peptide as the same specific fragment of fibrinopeptide A when
submitted to Mascot.

fragmentation. Fragmentation of a large portion of the isotope envelope was best
achieved by targeting a peak in the isotope window slightly above the monoisotopic peak,
in this case 714.5 and 844.9. The MCA setting in the instrument method profile allowed
for the summation of all 120 MS/MS spectra as they were taken. These MCA-summed
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spectra greatly increased MS/MS fragmentation intensities (Figures 2.17, 2.18). Several
runs of the same specimen, each at different staged collision energies between 15 and 30
for peak 714.2 and between 25 and 45 for 844.6, were carried out. Higher collision
energies produced smaller fragments and lower collision energies produced larger
fragments, allowing for better coverage of the entire sequence (Figure 2.19). Summed
spectra (120) from individual runs at each of 7 collision energies were then compiled to
provide even further signal and signal-to-noise enhancement (Figure 2.16). This allowed

Figure 2.19. Peak fragmentation at different collision energies. The index peptide at m/z 714.2
was selected for fragmentation at seven different CEs. The seven spectra were overlaid: blue =
CE 15, black = CE 17, red = CE 20, purple = CE 22, green = CE 25, maroon = CE 27, grey = CE
30. Higher CEs produced smaller fragments (a) while lower CEs produced larger fragments (b).
The use of multiple collision energies allowed for more complete fragmentation of the parent ion.

for daughter ion fragment coverage of 33 of the 39 amino acids for the peptide of m/z
714.2 and of 42 out of 47 amino acids for the peptide with m/z of 844.6 peptide (Tables
2.4 and 2.5).
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MS/MS Data Analysis
Those fragmentation data representing ions with charges of +3 or greater were
converted to the +1 ion mass using Excel as described above and compiled manually into
a text file which was then submitted to a searchable sequence database, Mascot. The
results of the submission are summarized in Tables 2.4 and 2.5. The amino acid
sequences were successfully deduced by Mascot from the peptide fragmentation data.
Specifically, the 714.2 peptide was identified as having a peptide sequence of
VSCKTSGYTFTEHGITWVRQAPGQGLECMGWISAHNGN which is a peptide
fragment of the immunoglobulin G heavy chain variable region. The 844.6 peptide was
identified as having a amino acid sequence of
TFPGFFSPMLGEFVSETESRGSGSGIFTNTKESSSHHPGIAEFPSRG which is a
fibrin alpha isoform C-terminal fragment (Figure 2.20). The sequences were also
submitted to a BLAST search on the National Center for Biotechnology Information site,
which confirmed the initial identification (Data not shown). Standard IDA fragmentation
did not result in selection of these peaks for MS/MS analysis and consequently did not
provide their amino acid sequences. Moreover, a single spectrum taken at the apex of the
elution profile for peak 714.2 showed 40 co-eluting peaks with intensities higher than it
also not selected for IDA. Similarly, 23 coeluting peaks had intensities greater than that
of peak 844.6 and were not selected by IDA. For these particular peptides, having the
MCA off also resulted in inadequate peak height and data quality for sequence
identification.
When 0.5 μg of the ACN-precipitated serum was subjected to fragmentation using
IDA with a rolling collision energy, 488 total peptides were selected for fragmentation.
However, only 5 of the 488 fragmentation studies resulted in protein identification when

77

the spectra were submitted to Mascot. In order to provide a comparison of the
instrument’s standard IDA approach to peptide sequencing to our customized method,
one of the peaks identified by IDA was further studied by our method. For this peptide
two additional modes of operation were tried in an effort to define the benefit of using the
MCA function. Using the peptide peak having a +2 charge state at m/z 733.4 for these
studies, we collected 120 MS/MS scans of the peak at a constant CE of 30, with the MCA
both on and off (Figure 2.21). The signal intensity of the fragmentation spectra collected
with MCA on was over 500 times higher than that collected without MCA. Nevertheless,
given the high abundance of the peptide, both fragmentation sets also resulted in spectra
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Figure 2.20. Fragmentation spectra of the index peptides 714.2 and 844.6 produced by
submitting charge-corrected peak lists to Mascot. Green lines show fragmentation
assignments. A and b ions are those that retained the charge on the N terminus, and y ions are
those that retained the charge on the C terminus. Those peaks that represent fragments that retain
two positive charges are denoted with a ++, those which have lost ammonia are denoted with an
*, and those which have lost water with a º.
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of sufficient coverage and intensity for Mascot identification, even with the single CE
(Figure 2.18). This peptide was identified by all three approaches to be a fragment of
fibrinopeptide A.

Figure 2.21. 13C isotope envelope and relative intensity of the peptide at m/z 733.4 selected
for method comparison. The peptide chosen for this study had a charge state of +2 and an intensity
of 48, relatively high compared to other molecular species that eluted at the same time.

Discussion
The goal of this study was to demonstrate that effective serum proteomics could
be carried out using capillary liquid chromatography, electrospray-ionization time-offlight mass spectrometry and that the initial cLCMS step could be followed seamlessly
with cLCMS/MS analyses to sequence and identify substantially larger peptides than had
previously been reported using CID for fragmentation. This approach is especially
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attractive because the cLCMS/MS peptide sequencing uses the same column, gradient
and MS instrumentation and does not require complete purification of the candidate, a
digestion step, development of a second LC step, characterization of SELDI surface
chemistry and potentially other steps that may be necessitated by using a second MS
approach to sequence peptides of interest.
The use of cross-platform analysis adds complexity to some intact-protein-based,
“top down” methods of biomarker discovery and identification. (Bogdanov 2005) Intact
protein-based approaches use individual protein mass and elution characteristics to locate
a single species and allow for evaluation of quantitative differences between comparison
groups that might make it a useful biomarker. The larger size of proteins in an intactprotein-based approach, as well as the high potential for increased protein variability due
to post-translational modifications, makes identification of serum proteins of interest by
MS/MS most often prohibitively difficult. Additionally, both fragmentation and
subsequent MS/MS amino acid sequence analysis become more complicated and less
sensitive with increasing peptide length. (Loo 1988, Horn 2000) At the same time, it is
becoming increasingly evident that peptide fragments of larger proteins may also prove to
be important, perhaps even better, biomarkers. For example, the most widely used
marker for prostate cancer is prostate specific antigen (PSA), which has a molecular
weight of ~30,000. (Diamandis 2004, Qian 2006) Current PSA assays determine
concentration of the intact molecule, but recent studies have suggested that specific
fragments of PSA provide better sensitivity and specificity. (Petricoin 2006, Mikolajczyk
2004) This underscores the potential importance of a specific peptide approach in the
search for new biomarkers.
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Y
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6
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7
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8
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9
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N
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2

39

T
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1

Table 2.4. Mascot Search Results for 714.2 peak. The corrected data list was submitted to a
MASCOT database searching the NCBInr database. The amino acid sequence was successfully
identified as a fibrinogen, or fibrin alpha isoform C-terminal fragment. The 71 peptide fragments
matched (in red) represent a sequence coverage of 33 of the 39 amino acids in the peptide.
Fragment ions in the a and b columns are those with the charge retained on the N terminus with
the protein backbone fragmented at the Cα-CO bond or the peptide amide bond respectively.
Fragment ions in the y column are those with the charge retained on the C terminus with the
protein backbone fragmented at the peptide amide bond. In addition, peaks are seen for ions that
retain two positive charges denoted a++, b++, and y++, and those which have lost ammonia (-17)
denoted a*, b*, and y*.

82

b++

#

b

1

102.0550

2

249.1234

125.0653

4

403.1976

202.1024

b*

b*++

b0

b0++

Seq.

231.1128

116.0600

F

y

y++

y*

y*++

y0

y0++

#

Our
described use of the
MCA
feature allowed for greatly increased signal-to51.5311
84.0444
42.5258 T
47
4961.3111 2481.1592 4944.2845 2472.6459 4943.3005 2472.1539 46

173.5917
328.1656 164.5864 spectra
2407.6250 4797.2161
3 346.1761
P 4814.2427
2399.1117
45
noise
of the
daughter ion fragmentation
produced
at each
CE 4796.2321
used. 2398.6197
In contrast
to
385.1870

193.0971

G

4717.1899 2359.0986 4700.1633 2350.5853 4699.1793 2350.0933 44

averaging of fragmentation spectra, summation of spectra collected at each of several CE
5

550.2660

275.6366

532.2554

266.6314

F

4660.1684 2330.5879 4643.1419 2322.0746 4642.1579 2321.5826 43

6

697.3344

349.1708

679.3238

340.1656

F

4513.1000 2257.0536 4496.0735 2248.5404 4495.0895 2248.0484 42

7

784.3664

392.6869

766.3559

383.6816

S

4366.0316 2183.5194 4349.0051 2175.0062 4348.0210 2174.5142 41

9 1012.4597

506.7335

994.4491

497.7282

M

4181.9468 2091.4770 4164.9203 2082.9638 4163.9363 2082.4718 39

levels
resulted
spectrum
that provided
good
fragmentation
data
863.4086 432.2080
2131.4902
4260.9890 2130.9981
8 881.4192
441.2132 in a single summary
P 4278.9996
2140.0034 4261.9730
40 for
554.2702
2025.9568
4033.8798
2017.4435
4032.8958 approach
2016.9515 38 for
10 1125.5437
1107.5332
L 4050.9063
the
entire 563.2755
peptide. In contrast,
using
the IDA
mode,
which
is the
standard
11 1182.5652

591.7862

1164.5546

582.7810

G

12 1311.6078

656.3075

1293.5972

647.3022

E

3880.8008 1940.9040 3863.7743 1932.3908 3862.7903 1931.8988 36

3937.8223 1969.4148 3920.7957 1960.9015 3919.8117 1960.4095 37

14 1557.7446

779.3759

1539.7340

770.3707

V

3604.6898 1802.8485 3587.6633 1794.3353 3586.6793 1793.8433 34

16 1773.8192

887.4133

1755.8087

878.4080

E

3418.5894 1709.7983 3401.5628 1701.2851 3400.5788 1700.7930 32

identification
of ions in a complex
specimen, selects only the 3 most abundant molecular
1440.6656 720.8365 F 3751.7582 1876.3828 3734.7317 1867.8695 3733.7477 1867.3775 35
13 1458.6762 729.8417
species
fragmentation,
i.e. the
top 3488.5949
18 most
abundant
822.8920 a spectrum for
1626.7661
813.8867 S 3505.6214
1753.3143
1744.8011
3487.6108 peptides
1744.3091 33 every
15 1644.7766within
1645.2770 3272.5202species
1636.7638 3271.5362
1636.2718 31of
minute. The IDA approach works well with3289.5468
high abundance
in specimens
17 1874.8669

937.9371

1856.8563

928.9318

T

18 2003.9095 1002.4584

1985.8989

993.4531

E

3188.4991 1594.7532 3171.4726 1586.2399 3170.4885 1585.7479 30

19 2090.9415 1045.9744

2072.9310 1036.9691

S

3059.4565 1530.2319 3042.4300 1521.7186 3041.4460 1521.2266 29

21 2304.0641 1152.5357 2287.0375 1144.0224 2286.0535 1143.5304

G

2816.3234 1408.6653 2799.2968 1400.1521 2798.3128 1399.6600 27

23 2520.1387 1260.5730 2503.1122 1252.0597 2502.1282 1251.5677

E

2672.2699 1336.6386 2655.2433 1328.1253 2654.2593 1327.6333 25

moderate
complexity; however, in the analysis of something as complex as serum, less20 2247.0426 1124.0250 2230.0161 1115.5117 2229.0321 1115.0197 R 2972.4245 1486.7159 2955.3979 1478.2026 2954.4139 1477.7106 28
abundant
peptides
will1187.5384
often2373.0856
be overlooked.
In these
experiments,
a single
spectrum
2374.0696
1187.0464 S 2759.3019
1380.1546
2742.2754 1371.6413
2741.2914 1371.1493
22 2391.0961 1196.0517
26
2543.2273 1272.1173 2526.2008 1263.6040 2525.2167 1263.1120
taken at the apex of the elution profile for peak
714.2 showed the presence of 40
24 2607.1707 1304.0890 2590.1442 1295.5757 2589.1602 1295.0837

S

24

25 2664.1922 1332.5997 2647.1657 1324.0865 2646.1816 1323.5945

G

2456.1953 1228.6013 2439.1687 1220.0880 2438.1847 1219.5960 23

26 2777.2763 1389.1418 2760.2497 1380.6285 2759.2657 1380.1365

I

2399.1738 1200.0905 2382.1473 1191.5773 2381.1632 1191.0853 22

28 3025.3924 1513.1998 3008.3658 1504.6865 3007.3818 1504.1945

T

2139.0213 1070.0143 2121.9948 1061.5010 2121.0108 1061.0090 20

coeluting
peaks with intensities higher than that of the peak of interest omitted by IDA.
27 2924.3447 1462.6760 2907.3181 1454.1627 2906.3341 1453.6707 F 2286.0898 1143.5485 2269.0632 1135.0352 2268.0792 1134.5432 21
3122.4087found
1561.7080in3121.4247
1561.2160
1019.4905peak
2020.9471
1010.9772
2019.9631 its
1010.4852
29 3139.4353 1570.2213
N 2037.9737
19
Similarly,
23 peaks
the mass
spectrum
where
844.6
reached
maximum
30 3240.4830 1620.7451 3223.4564 1612.2318 3222.4724 1611.7398

T

1923.9307

962.4690 1906.9042

953.9557 1905.9202

953.4637 18

were more abundant than it and were also omitted by IDA. Even if selected902.9399
for
31 3368.5779 1684.7926 3351.5514 1676.2793 3350.5674 1675.7873

K

1822.8831

911.9452 1805.8565

903.4319 1804.8725

17

32 3497.6205 1749.3139 3480.5940 1740.8006 3479.6100 1740.3086

E

1694.7881

847.8977 1677.7615

839.3844 1676.7775

838.8924 16

33 3584.6525 1792.8299 3567.6260 1784.3166 3566.6420 1783.8246

S

1565.7455

783.3764 1548.7190

774.8631 1547.7349

774.3711 15

S

1391.6814

696.3444 1374.6549

687.8311 1373.6709

687.3391 13

fragmentation
IDA,
those3653.6740
ions may
product
fragmentation
3654.6580
1827.8327
1827.3406not
1478.7135 739.8604
1461.6869
731.3471 1460.7029 spectra
730.8551 14of
34 3671.6846 1836.3459 by
S generate
35 3758.7166 1879.8619 3741.6901 1871.3487 3740.7060 1870.8567

643.8231 12
sufficient intensity or quality to be useful. When an aliquot of the ACN-precipitated
36 3895.7755 1948.3914 3878.7490 1939.8781 3877.7650 1939.3861

H

1304.6494

37 4032.8344 2016.9209 4015.8079 2008.4076 4014.8239 2007.9156

H

38 4129.8872 2065.4472 4112.8606 2056.9340 4111.8766 2056.4419

P

1030.5316

40 4299.9927 2150.5000 4282.9662 2141.9867 4281.9821 2141.4947

I

42 4500.0724 2250.5398 4483.0459 2242.0266 4482.0618 2241.5346

E

652.8283 1287.6229

644.3151 1286.6388

584.2989 1150.5640

575.7856 1149.5799

575.2936 11

515.7694 1013.5050

507.2562 1012.5210

506.7642 10

876.4574

438.7323

859.4308

430.2190

858.4468

429.7270

8

692.3362

346.6717

675.3097

338.1585

674.3256

337.6665

6

1167.5905

serum
was subjected to fragmentation using 933.4788
IDA with
rolling collision energy, 488 total
467.2431 916.4523 458.7298 915.4683 458.2378 9
39 4186.9086 2093.9580 4169.8821 2085.4447 4168.8981 2084.9527 G
peptides
were selected
for fragmentation
but763.3733
only 5382.1903
could746.3468
be identified
by Mascot.
4354.0033 2177.5053
4353.0193 2177.0133 A
373.6770 745.3627
373.1850 7 All 5
41 4371.0298 2186.0185
282.1504 546.2671 273.6372 545.2830 273.1452 5
43 4647.1408 2324.0740 4630.1143 2315.5608 4629.1303 2315.0688 F
sequenced
peptides were different fragments563.2936
of fibrinopeptide
A and were among the
44 4744.1936 2372.6004 4727.1670 2364.0872 4726.1830 2363.5951

P

416.2252

208.6162

399.1987

200.1030

398.2146

199.6110

4

45 4831.2256 2416.1164 4814.1991 2407.6032 4813.2150 2407.1112

S

319.1724

160.0899

302.1459

151.5766

301.1619

151.0846

3

47

G

76.0393

38.5233

very
most abundant species observed among232.1404
all spectra
and all were in lower charge
116.5738 215.1139 108.0606
46 4987.3267 2494.1670 4970.3002 2485.6537 4969.3162 2485.1617 R
2
1

states.
It isMascot
also worth
out844.6
thatm/z
thepeak.
IDAThe
function
does
for selection
of a
Table 2.5.
Searchpointing
Results for
corrected
datanot
list allow
was submitted
to a
MASCOT database searching the NCBInr database. The amino acid sequence was successfully identified
as a fibrinogen,
or fibrin
alpha isoform
C-terminal
fragment. The 95 peptide fragments matched (in red)
specific
peptide
that might
be of clinical
interest.

represent a sequence coverage of 42 of the 47 amino acids in the peptide. Fragment ions in the b column
are those with the charge retained on the N terminus with the protein backbone fragmented at the peptide
amide bond. Fragment ions in the y column are those with the charge retained on the C terminus with the
protein backbone fragmented at the peptide amide bond. In addition, peaks are seen for ions that retain
two positive charges denoted b++, and y++, those which have lost ammonia (-17) denoted b*, and y*, and
those which have lost water (-18) denoted bº, and yº.
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In contrast to IDA, cLCMS/MS fragmentation of a specific peptide can be
accomplished with the MCA setting turned either off or on. With the MCA setting turned
off, the method can be set up to take the periodic MS survey scans of all ions in the
sample between MS/MS fragmentation scans so as to track the both progress of the run
and the elution of specific peptides. Even though the duty cycle allows for one spectrum
to be taken every second, the software only allows for consideration of the average of all
the cLCMS/MS spectra taken within a selected time window. Summation of spectra is
not possible with data collected using this method. Signal-to-noise ratios of individual
cLCMS/MS spectra of low abundance peptides are low, and the signal-to-noise of
averaged spectra are even lower. In contrast, with the MCA setting turned on, there is no
option to use MS survey scans, and so run progress and elution times cannot be tracked
simultaneously, but spectra can be summed as they are taken within a specified time
window. This increases signal-to-noise ratios even more than summation of spectra. The
cLCMS/MS runs targeting a specific peptide can only use one CE setting per run,
regardless of whether the MCA setting is turned on or off. However, multiple
cLCMS/MS runs covering a range of CE values appropriate to the size of the peptide
being targeted (determined empirically) can be carried out and compiled which allowed
for both good signal-to-noise ratios of daughter ions as well as good fragmentation
coverage over the length of the peptides (Figure 2.20). The use of the MCA was critical.
When the MCA was off, the two index peptides considered were not identified by their
fragmentation data. The increased intensity provided by the summed spectra made the
spectra much easier to interpret. However, we recognize that not every low abundance
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peptide will be sequenced with this customized approach despite improved fragmentation
coverage and peak intensities.
A more direct comparison of IDA to our method was made for one of the peptides
identified by IDA. The peptide evaluated had a +2 charge at m/z 733.4 (Figure 2.21).
Using our approach, we collected 120 MS/MS scans of this peak at a constant CE of 30,
with the MCA both on and off. Although the signal intensity of the fragmentation spectra
collected with MCA was over 500 times higher than that collected without MCA, both
spectra produced fragmentation data of sufficient quality for identification, even with a
single CE (Figure 2.18). Both of the customized approaches allowed for Mascot
identification of this peptide as the same specific fragment of fibrinopeptide A as found
using IDA.
Large peptides frequently appear as multiply charged species in the cLCMS
spectra. Two complications arise from this. First, while Analyst and other software
programs usually assign charge states of +1 and +2 correctly, peptide fragments with a
charge of +3 or higher are often misclassified. This necessitated a manual comparison of
the data list generated by many MS computer software analyses to the actual spectra to
correct charge assignment mistakes. Second, Mascot considers only +1 and +2 daughter
fragment ions when comparing experimental data to database protein sequences. For this
reason, we manually converted all daughter fragment ions with charge states greater than
+2 to their respective +1 m/z values before submitting the converted data list to Mascot.
The MOWSE scoring algorithm used by Mascot to determine sequence identification
confidence limits takes into account all possible theoretical fragments. This score is
calculated as the logarithm (-10 × log (p)) of the probability (p) that the sequence ID that
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was made by comparing the fragmentation spectra to the database is a chance event
(www.matrixscience.com). Despite fragments accounting for 42 of 47 amino acids for
peak 844.6, this represented only 95 fragments out of a theoretical 508 possible and the
Mascot search returned a Mowse score of 24. For this particular search, a score of > 23
indicated peptides with significant homology, while individual ions required scores > 63
to indicate identity or extensive homology (p<0.05). While a score of 24 suggested some
homology, such a score would not, in and of itself, provide much confidence in the
sequence matched to the spectra, but a protein BLAST search of the amino acid sequence
deduced by MASCOT provided an E value of 5x10–18, indicating a high degree of
certainty in peptide assignment.
In summary, the approach described here provides a dramatic enhancement in the
peptide sequencing/protein identification capabilities of cLCMS plus cLCMS/MS serum
proteomics. The possible application of this approach to serum biomarker discovery by
making direct comparisons between sera of individuals with a disease to the sera of those
who do not will require additional work. In particular, making serum proteomics
quantitative will be important. Quantitation by means of MS is challenging and
continues to be a major concern in the analysis of complex specimens, especially when
coupled to specimen preprocessing, chromatographic inconsistencies, variable ionization
efficiencies and fluctuations in instrument performance. Previous serum proteomic
studies demonstrate these difficulties, but to date there have been no effective remedies
for such potential problems. Clearly, future work will need to address these issues.
(Mikolajczyk 2004) Due to the empirical nature of this method, it is not likely that this
method would be easily automatable. As recently stated by Mujezinovic et al. “…no
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automated procedure will match the performance of the experienced eye and the intuition
of an MS specialist in the foreseeable future.” (Baggerly 2004) Hence, more
sophisticated data analytical techniques represent another need for successful biomarker
discovery.
In conclusion, the successful observation and identification of two index peptides
of 39 and 47 amino acids from a single serum sample, using combined cLCMS and
cLCMS/MS methods as part of a single platform exceed previously published size limits
for LC-MS/MS and suggest that these techniques can be useful in clinical biomarker
discovery.
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Chapter 3 – Proteomic Identification of Serum Peptides
Predicting Subsequent Spontaneous Preterm Birth
Abstract
Background
Current interventions to prevent spontaneous preterm birth (SPTB) are most efficacious if
administered prior to advanced active labor. We used a proteomic approach to identify
markers of SPTB in the serum of women at 24 and 28 weeks gestation prior to the onset
of symptoms.

Methods
Serum proteomics was applied to sera from 80 pregnant women sampled at 23.4 weeks
gestation (range 22-24 wks) and an additional 80 pregnant women sampled at 27.6 weeks
(range 26-29 wks). Half of these women at each time had uncomplicated pregnancies
with term deliveries and half had pregnancies resulting in SPTB. Additional analytes had
been previous assayed in these specimens.

Results
Three specific peptides arising from inter-alpha-trypsin inhibitor heavy chain 4 protein
were reduced significantly in the serum of women with later SPTB. The differences were
observed for women at both 24 and 28 weeks gestation, approximately 8 and 4 weeks
prior to SPTB. Levels of these peptides were lower the more imminent the SPTB.
Likewise their positive predictive values were higher at 28 weeks. The peptide mass
2027 was the most discriminating with a sensitivity of 65% with a specificity of 82.5%,
OR=8.8, CI: 3.1-24.8 at 28 weeks. The 3 current peptide biomarkers when combined
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with 6 previously studied candidate biomarkers provided a specificity of 86.5% and a
sensitivity of 80.5% at 28 wks.

Conclusion
Three novel serum markers of SPTB have been identified using a serum proteomic
approach. Using these markers and 6 previously considered markers, women at greater
risk of SPTB can be identified weeks prior to SPTB allowing for medical intervention.
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Introduction
Spontaneous preterm birth (SPTB) is the leading cause of perinatal morbidity and
mortality in the United States. (Rush 1976, Goldengerg 1998) Despite the magnitude of
the problem and the substantial research efforts of many investigators, completely
efficacious therapies for the treatment or prevention of SPTB have yet to be developed.
Indeed, the rate of SPTB has not changed in decades. (Hoyert 2006) A major obstacle to
the development of an effective treatment for preterm labor is a limited understanding of
the molecular events required to initiate and maintain term and preterm labor.
Several proteins present in maternal serum or cervical secretions have been
proposed as markers that may predict SPTB. Goldenberg and associates, in perhaps the
most comprehensive study to date, evaluated a screening test consisting of three serum
markers (CRH, AFP, alkaline phosphatase) and two cervical secretion markers (fetal
fibronectin and ferritin). (Goldenberg 2001) This use of multiple markers increased
sensitivity, specificity and the odds ratio of the predictive test. (Goldenberg 2001)
However, none of the current SPTB markers alone or in combination provided adequate
specificity or sensitivity to be used predictively.
Recent advances in technology allow for the evaluation of a large, unbiased
portion of the complement of peptides and/or proteins present in maternal serum. Serum
proteomic analysis, consisting of chromatographic separation followed by mass
spectrometry to identify peptides and proteins by mass, can provide an extensive
inventory of peptides and/or proteins present at any given time. Previous studies have
attempted to use proteomic patterns to identify patients with early ovarian, breast and
prostate cancers. (Buhimschi 2005) The use of proteomic analysis to identify phenotypic
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molecular characteristics of women who experience SPTB or infection has been
attempted in amniotic fluid (Gravett 2004, Buhimschi 2005, Ruetschi 2005, Buhimschi
2007) and cervical secretions (Iams 1996, Ruetschi 2005, Gravett 2007, Pereira 2007),
but serum proteomic analysis has not been reported.
SPTB is well suited for a proteomic approach given likely serologic changes that
precede by weeks its clinical manifestations. We hypothesize that proteomic differences
exist in maternal serum several weeks prior to the onset of clinical symptoms in women
destined to develop SPTB. Our aim was to use serum proteomics to differentiate women
having a later SPTB from those having term deliveries. Moreover, we hoped to identify
all peptides that are found to be increased or decreased in the serum of women who go on
to have a SPTB as compared to those who deliver at term.

Methods
Patient Population
This study represents a nested case-control study that used samples and data that
were collected during the National Institute of Child Health and Human Development
Maternal-Fetal Medicine Units Network Preterm Prediction Study (Merrell 2004). The
Preterm Prediction Study, conducted between 1992 and 1994, was a multicenter
observational investigation of 2929 symptom-free women evaluated longitudinally to
determine risk factors for spontaneous preterm birth. Women were enrolled in this study
without regard to specific risk factors for spontaneous preterm birth. Extensive
information and biologic specimens were collected at each of 4 study visits, beginning at
approximately 22 to 24 weeks’ gestation and occurring at 2-week intervals. The overall
study population and the methods used in the Preterm Prediction Study have been
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previously described in detail. Gestational age was based on the last menstrual period if
the last menstrual period–derived gestational age was confirmed within 10 days by the
earliest ultrasonographic evaluation. A spontaneous preterm birth was defined as a
preterm birth < 35 weeks gestation occurring as the result of the spontaneous onset of
labor or spontaneous ruptures of membranes.
Serum was collected at 24 and 28 weeks gestation and pregnancy outcomes were
obtained. Participating women provided voluntary, informed consent. The original study
protocols as well as these secondary analyses were approved by the representative
institutional review boards. For this study, serum from 40 subjects who experienced a
later SPTB and 40 subjects having uncomplicated pregnancies were obtained at 24 wks
gestation (Visit 1) and submitted to proteomic analysis. Additionally, serum from 40
subjects who experienced a later SPTB and 40 subjects having uncomplicated
pregnancies that ultimately delivered at term after spontaneous onset of labor was
obtained at 28 wks (Visit 3) gestation and was likewise analyzed. Cases and controls
were randomly selected to produce a representative group from among the cohort.
Researchers were blinded to which group represented controls and which cases during the
proteomic analysis and data evaluation.

Specimen Preparation
High molecular weight, and typically uninformative, proteins were removed by
organic solvent precipitation as described in chapter 2.
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Capillary Liquid Chromatography
Capillary liquid chromatography (cLC) was interfaced with a mass spectrometer,
allowing for the continuous direct delivery of fractionated, protein-depleted serum to the
mass detector. A complete description of this is provided in Chapter 2.

Electrospray-Ionization, Time-of-Flight Mass Spectrometry
Effluent from the cLC was directed into a QSTAR® Pulsar i quadrupole
orthogonal time-of-flight mass spectrometer through an IonSpray source (Applied
Biosystems). Mass spectra were collected every second for m/z 500 to 2500 from 5 to 55
min elution. Data collection and preliminary formatting were accomplished using
Analyst QS® software with BioAnalyst add-ons (Applied Biosystems). Specimens from
cases and controls were analyzed together in randomized order.
To reduce data file size, each mass chromatogram was divided into ten 2-minute
elution intervals. One reference peak, observable in all specimens, near the center of
each interval, and which did not demonstrate differences in abundance between the two
groups was used to align time in that elution region. Of the ten elution intervals, the first
to be analyzed (and the only one reported here) was the second 2 min window, chosen
because more peptides were present. Systematic manual inspection of each case and
control spectrum identified candidate species for further analysis. (Merrell 2008)

Evaluation of Candidate Molecular Species
Each species that appeared quantitatively different between groups was further
evaluated. To facilitate determination of statistically significant quantitative differences,
a second peak near the candidate peak but quantitatively comparable as determined by
visual inspection of a sample of individual mass spectra in both groups was selected as an
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internal control. This reference peak was then used to normalize the candidate peak of
interest, correcting for variability in specimen processing, specimen loading, ionization
efficiency and instrument performance and allowing comparison across runs performed
on different days. Thereafter, the molecular species were 'extracted' by the Analyst®
software to determine a quantitative peak height of both candidate and reference ions in
each specimen for all subjects.

Mass Spectral Data Analysis
The abundance (peak height) of each candidate and reference species was
tabulated as was the calculated ratio of each candidate species abundance relative to
reference species abundance within each patient. The log of that ratio was also
determined because abundance varied substantially. The data were submitted to
statistical analysis.

MS-MS Amino Acid Sequencing
Candidate species demonstrating statistically different abundances between cases
and controls were further analyzed in an effort to chemically identify the candidate
molecule. Frozen supernatant (from the protein reduction step) was thawed and hand
injected for MS-MS analysis with a one sec TOF-MS scan being taken for m/z of 500 to
2500, followed by a 3 sec Positive Product Ion scan taken to the collision cell and the
second MS sector to study the ion of interest. The selected ion was fragmented by N2 gas
collision and the daughter fragments 'read' in the second MS.
MS-MS fragmentation data were produced at several discrete collision energies,
unique to the peptide's size, and all the fragment data summed. The spectrum were
visually inspected and compared to the exported data list to insure the software had
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assigned charge states correctly. After any correction, the data list was transformed using
the formula: +1 mass = m/z value * charge – (charge – 1) so that all species had a +1
mass listed. The corrected list was submitted to Mascot (www.matrixscience.com), a
searchable MS database allowing protein/peptide identification. Amino acid sequences
were also independently submitted to the short homologous or near homologous protein
BLAST search available through the NCBI website as a confirmation.

Previous Biomarker Analysis
Plasma corticotrophin releasing factor, defensin, ferritin, lactoferrin, thrombin
anti-thrombin complex and tumor necrosis factor α receptor type 1 assays have been
previously described. (Goldenberg 2001)

Statistical Analysis
Data are expressed as means + 1 standard error. Species that appeared to be
quantitatively different were considered. Only three peaks were evaluated further.
Comparisons of the abundance of a single species for the two study populations were
carried out by the Wilcoxon rank sum test. Comparisons were carried out for each
candidate at both 24 and 28 wks gestation. Twenty three additional serum markers were
previously assayed in these samples and comparisons of the abundance of each individual
marker were calculated using Wilcoxon rank sum test. Logistic regression analyses were
performed for the three novel biomarkers. These three in combination with the best 6 of
the previously tested markers were used for classification performance by means of
receiver operator curves. For all statistical tests, nominal two-sided P-values are reported
with statistical significance defined as a P-value < 0.05. SAS version 8.2 (SAS Institute,
Cary, North Carolina) was used for these analyses.
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Results
The demographics of the four groups (Case and Control at Visit 1 and Case and
Control at Visit 2) are provided in Table 3.1.

Maternal Age (year)
GA at Delivery (wk)
Time from Visit 1 to Delivery
(wk)
Parity (% nulliparous)
Race (% African American)

24 Weeks
Controls
N=40
23.2 + 0.83
38.9 + 0.19
15.1 + 0.18

24 Weeks
Cases
N=40
23.6 + 0.81
31.4 + 0.44*
7.8 + 0.45*

28 Weeks
Controls
N=40
24.3 + 0.9
38.9 + 0.18
15.1 + 0.18

28 Weeks
Cases
N=40
24.2 + 0.94
32.3 + 0.28*
8.6 + 0.31*

30.0
75.0

32.5
70.0

30.0
77.5

32.5
67.5

Table 3.1. Demographics of four preterm birth groups (* p<0.001)
The individual mass spectra were averaged for the 2-minute window that was
analyzed. Within these 10 cLC windows 4000-5000 unique ion peaks were detected.
Our initial survey involved the second time window, selected because more peptides
were observable.
After visual inspection, four molecular ions were further evaluated to determine if
quantitative differences were significant. Of the 4 species considered further, 3 were
found to be quantitatively significantly different (Table 3.2). Those species were: an ion
at 676.66 m/z with a +3 charge corresponding to a neutral parent mass of 2026.98 Da; an
ion at 856.85 m/z with a +5 charge corresponding to a neutral parent mass of 4279.25 Da;
and an ion at 860.05 m/z with a +5 charge that corresponded to neutral parent masses of
4295.25 Da. The exact peak height of each of these species as well as a reference ion
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24 Weeks Gestation
Preterm Birth

Control

Label
Peak at 677(/673) m/z

Mean
0.198

Std Error
0.076

Mean
0.503

Std Error
0.094

P Value
0.007

Peak at 857(/843) m/z

-0.137

0.086

0.284

0.092

0.002

Peak at 860(/843) m/z

-0.376

0.088

0.009

0.098

0.005

P Value

28 Weeks Gestation
Preterm Birth

Control

Label
Peak at 677(/673) m/z

Mean
-0.015

Std Error
0.090

Mean
0.579

Std Error
0.101

Peak at 857(/843) m/z

-0.149

0.095

0.231

0.102

< 0.0001
0.007

Peak at 860(/843) m/z

-0.204

0.088

0.201

0.095

0.002

Table 3.2. Ion abundance of the candidate peaks log ratioed to reference.

24 Weeks Gestation
Preterm Birth

Control

Label
Placental growth factor

Mean
446.82

Std Error
45.99

Mean
596.69

Std Error
63.36

P Value
0.05

Thrombin anti-thrombin

274.80

255.91

293.83

269.60

0.02

28 Weeks Gestation
Preterm Birth
Label
Corticotropin releasing
factor

Control

Mean
0.3585

Std Error
0.0189

Mean
0.2844

Std Error
0.0122

P Value
0.0006

Defensin

612.0

106.6

427.4

92.1

0.039

Ferritin

18.97

3.37

10.00

1.48

0.043

Lactoferrin

245.0

42.0

484.6

100.7

0.046

Thrombin anti-thrombin

546.8

366.3

835.5

453.7

0.044

1114.1

119.0

880.4

33.7

0.018

TNF receptor type 1

Table 3.3. Comparison of relative abundance of other potential markers in the
serum of cases and controls.

nearby was determined by the instrument. These same ion species were studied at both
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24 and 28 wks gestation visits and were found to be significantly different between cases
and controls at both gestational ages. Other potential markers with significant difference
in abundance between cases and controls are listed in Table 3.3.
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Figure 3.1 A. ROC curves demonstrating the predictive capability of 3 peptide
markers to predict subsequent SPTB after sampling at 24 and 28 weeks. Area under the
curve and 95% confidence intervals are also included for each marker at each visit.

Predictive value of the markers
The sensitivity of each of the three biomarkers improved generally from 24 to 28
weeks (At 24 weeks: 677, sensitivity=35.0%, specificity=92.5%, OR=6.64, CI 1.7-25.5;
857, sensitivity=45.0%, specificity=82.5%, OR=3.86, CI 1.4-10.8; 860,
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0.6
0.4
0.2

True Positive

0.8

1.0

Combination of 9 predictors, Visit 3

0.0

AUC=0.894 (0.823-0.966), p<0.0001

0.0
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0.4
0.6
False Positive
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Figure 3.1 B. ROC curve demonstrating the predictive capability of the
combination of 9 predictors including peak 677, peak 857, peak 860, corticotrophin
releasing factor, defensin, ferritin, lactoferrin, thrombin antithrombin complex, and
tumor necrosis factor – receptor type 1 to predict subsequent SPTB after sampling at
28 weeks. Area under the curve and 95% confidence intervals are also reported.
sensitivity=45.0%, specificity=80.0%, OR=3.27, CI 1.2-8.8. At 28 weeks: 677,
sensitivity=65.0%, specificity=82.5%, OR=8.76, CI 3.1-24.8; 857, sensitivity=37.5%,
specificity=80.0%, OR=2.4, CI 0.9-6.6; 860, sensitivity=55.0%, specificity=80.0%,
OR=4.89, CI 1.8-13.2). The biomarker at m/z 676.7 was the best single predictor of
SPTB at 24 or 28 wks pregnancy. (Figure 3.1 A) Combination of the 3 markers did not
change the sensitivity and specificity but the inclusion of the 6 best additional markers
improved the sensitivity to 86.5% with a specificity of 80.5% at 28 weeks (Figure 3.1 B).
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Peptide Identification
Sequencing by means of a tandem MS/MS with intervening fragmentation
allowed for the complete amino acid sequence to be determined by amino acid homology
to known peptide or protein sequences. The amino acid sequences are provided in Table
3.4. The peaks initially assessed represented a +3 charge state for the species at 677 and
a +5 charge state for the species at 857 and 860. Molecular ions representing additional
charge states (+2 for 677, both +6 and +7 for 857 and 860) were also observed and were
m/z
Charge
MW
Amino Acid Sequence
________________________________________________________________________
677
+3
2026.98
qlglpgppdvpdhaayhpf
857

+5

4279.25

nvhsagaagsrmnfrpgvlssrqlglpgppdvpdhaayhpf

860

+5

4295.25

nvhsagaagsrm(O)nfrpgvlssrqlglpgppdvpdhaayhpf

Table 3.4. Amino acid sequences for the 3 biomarker peptides
also quantitatively significantly reduced in the women with later SPTB (Data not shown).
When a BLAST search of the individual amino acid sequences was performed using the
National Center for Biotechnology Information website, all three peptides were found to
be derived from one region of inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), the
common parent protein.

Relationship of Biomarker Abundance as a Function of Time to
Delivery
Women in the case group at 24 wks were on average 7.8+0.45 wks away from
their actual preterm delivery, the mean gestational age at delivery being 31.4+0.44 weeks.
Women in the case group at 28 wks were on average 4.7+0.32 wks removed from their
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Figure 3.2. A representative plot of one biomarker’s normalized abundance (m/z 857)
as a function of time to delivery (days). The correlation was statistically significant
(R2=0.11, p=0.003).

PTB, the mean gestational age at delivery being 32.3+0.28 weeks. When biomarker
abundance was plotted as a function of time to delivery, a significant correlation was
found for all three markers at 28 wks gestation (peak 677: R2=0.13, p=0.001, peak 857:
R2=0.11, p=0.003, peak 860: R2=0.12, p=0.002) and for two of the markers at 24 wks
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gestation (peak 857: R2=0.13, p=0.001, peak 860: R2=0.11, p=0.003). See Figure 3.2 for
a representative plot. Correlation for the third marker (peak 677) at 24 wks had a p-value
of 0.08 (R2=0.04). In each case abundance of the biomarkers was lower the nearer the
delivery. None of the markers demonstrated a correlation between its abundance and
gestational age, as would be expected given the narrow timing of specimen collection.

Relationship of Biomarker Abundance as a Function of Etiology of
PTB
In the subjects sampled at 24 weeks and 28 weeks, chorioamnioitis was confirmed
in only 4 of 80 subjects and 2 of 80 subjects respectively. Levels of all 3 biomarkers
were markedly reduced in women with confirmed chorioamnioitis, but the number of
subjects having this diagnosis was too small for meaningful statistical comparisons.
There was no reduction in the abundance of any of the biomarkers with fetal fibronectin
positivity.

Discussion
We have applied a serum proteomics method utilizing cLC-ESI-TOFMS to the
analysis of sera collected from pregnant women at 24 and 28 wks gestation. We have
identified 3 peptides within the serum of pregnant women at both 24 and 28 weeks
gestation that are significantly decreased in women who experienced a later SPTB. The
changes predated on average the SPTB by 7.8 wks and 4.7 wks respectively. All three
identified peptides came from a single protein and from a highly conserved proline-rich
region of that protein that had been processed differently. One of these peptides had an
oxidized methionine. The parent compound is termed inter-alpha trypsin inhibitor heavy
chain 4 (ITIH4), a glycoprotein that is a kallikrein-sensitive acute phase reactant (Piñeiro
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2004). The intact protein is known to be increased in inflammatory states (Piñeiro 2004),
but little is known about the function of this protein or its peptide fragments, including
possible biological activity. Peptides derived from ITIH4 that differ from the peptides
described here have demonstrated quantitative increases in sera of women with earlystage ovarian cancer (Song 2006). Other peptides arising from this same protein, but
differing from the peptides described here, appear to be increased in other cancers in a
disease specific manner (Song 2006). This might suggest differential peptide production
having a disease specific pattern.
Early efforts to carry out serum proteomics resulted in methodological
controversies. (Petricoin 2002 Lancet, Baggerly 2004) First, the use of computers to
evaluate mass spectral data is challenging. No software application has been accepted as
fully reliable. Hence, continual reference to the actual mass spectra is critical. Second,
day to day variability can be substantial for both the separation step and subsequent mass
spectral analysis. Much of the variability can be eliminated or dramatically decreased by
means of an internal control. Such standards are often used to correct for inconsistencies
in elaborate, multi-step analyses involving human serum. In this study, such controls
were employed by utilization of endogenous reference molecules present in all specimens
to compensate for variability in specimen processing, chromatography loading and
separation, ionization efficiency and instrumental performance.
Collectively, these data suggest strongly that the three peptides described here are
useful biomarkers, identifying approximately two thirds of pregnant women who will
delivery prematurely, weeks prior to the SPTB. These significant quantitative differences
were observed for both sets of women with later SPTB sampled at different gestational
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ages and were also significantly different for other charge states of the same peptides as
observed by MS. In addition, the data demonstrated a significant relationship between

Figure 3.1 C. Normalized biomarker abundance was calculated for all individuals at 28
weeks. The graph shows biomarker (m/z 677) abundance in the sera of women having a later
SPTB or term delivery. Sixty five percent (26/40) of the women with later SPTB had a value
below the threshold whereas only 17.5 (7/40) percent of women with a term delivery had a
value below the same threshold.
biomarker abundance and nearness to delivery, abundance being lower the closer the
SPTB. The sensitivity of the most discriminating peptide or for combinations of the 3
was 65% with a specificity of 82.5% (LR+=3.71, LR-=0.42). (Figure 3.1 C) However,
the data suggest that these markers may become better predictors of SPTB as women near
the event. It is also highly likely that additional biomarkers will be found that increase
the sensitivity and specificity of SPTB prediction. For example, when the current three
peptides were coupled to 5 previously tested candidate biomarkers, the sensitivity was
89.8% with a specificity of 81.0% (LR+=4.4, LR-=0.17).
The data do not allow for any confident differentiation of the biomarkers
according to a potential etiology for the SPTB. However, we hypothesize that women

104

with infectious etiology of their preterm birth will have lower levels of these 3 markers.
This will be the focus of future investigations.
The specimens utilized in this analysis were part of a multi-center study
representing 10 medical centers located across the US and represent a good mix of
subjects. However, it is recognized that these findings will need to be confirmed in a
larger number of specimens, preferably in a prospective fashion. In addition, studies of
active preterm and term labor are needed to define whether these changes are observed
only 4-8 wks prior to a preterm delivery or whether they are still present at the time of
active preterm labor and whether the changes in biomarker abundance are limited to
preterm births or also accompany term labor also.
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Chapter 4 – Serum Biomarkers that Allow Prediction of
Preeclampsia in Pregnant Women at 12-14 Weeks
Gestation.
Summary
Using a unique serum proteomics approach we have found 29 molecules that are
statistically quantitatively different in the serum of pregnant women at the end of their
first trimester that who will later develop preeclampsia (PE), a life threatening
complication of pregnancy. Five of these are sufficiently different that they each appear
to have utility in risk assessment of PE 3-6 months prior to there being any clinical
manifestations of PE. Seventeen of these markers appear to have utility in risk
assessment in weighted combinations for this same patient population. The polypeptide
sequences of two molecular species are provided. In addition, information is provided
that uniquely identifies five of these molecular species chromatographically without
knowledge of the polypeptide sequence.

Background
Preeclampsia is currently defined by an elevation in blood pressure (>140/90 mm
Hg) and protein in the urine (>300 mg/24 hr) occurring in the second half of pregnancy in
a women without a history of high blood pressure, kidney disease, diabetes or other
significant disease. Preeclampsia can include many other abnormalities and having one
or more these suggests severe preeclampsia.
Preeclampsia is estimated to affect 3-5% of all pregnancies in the U.S. and is one
of the leading causes of maternal death associated with pregnancy in the U.S. and is
estimated to result in ~75,000 maternal deaths each year worldwide.
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Currently there are no accepted biochemical markers for either the prediction or
diagnosis of PE. However, knowledge that a pregnant woman was at high risk for the
later development of PE or was at very low risk for the development of PE would be
useful to the clinician in terms of the frequency and intensity of antenatal surveillance
and potentially in therapeutic interventions for the mother or fetus.

Methods
Patient Population
This study involved 55 pregnant women having blood withdrawn between 12 and
14 weeks of pregnancy who were followed through the completion of their pregnancy.
Twenty seven of these women had uncomplicated pregnancies with no evidence of
preeclampsia (PE) including no increase in blood pressure or abnormal levels of protein
in their urine. These constitute the control group. Twenty eight of these women
developed later PE, each after 24 weeks of pregnancy. These women constitute cases.
The sera of these 55 women were studied using our proteomics approach.

Sample Preparation
This method has been described in detail in Chapter 2

cLC-MS Analysis
Capillary liquid chromatography (cLC) to fractionate or separate peptides and
proteins was performed using a 1 mm (16.2 µL) microbore guard column (Upchurch
Scientific, Oak Harbor, WA) and a 15 cm x 250 um i.d. capillary column. The guard
column was dry-packed and the capillary column was slurry packed in-house using
POROS R1 reversed-phase media (Applied Biosystems, Framingham MA). Column
equilibration and chromatographic separation was performed using an aqueous phase
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(98% HPLC grade H2O, 2% acetonitrile, 0.1% formic acid) and an organic phase (2%
H2O, 98% acetonitrile, 0.1% formic acid). Separation was accomplished beginning with
a 3 min equilibration at 95% aqueous solution, followed by a 2.75%/min organic phase
increase to 60% organic phase, which was increased at 7%/min to 95% organic phase.
The gradient is held at 95% organic phase for 7 min to elute the more hydrophobic
components of the sample, and then the gradient is returned to 95% aqueous phase over 5
min and held at this concentration for 2 min to re-equilibrate the column. Separations are
performed at a flow rate of 5 μL/min. The cLC uses an LC Packings Ultimate Capillary
HPLC pump system, with a FAMOS® autosampler (Dionex Corporation, Sunnyvale, CA)
controlled by Analyst QS® software (Applied Biosystems, Foster City, CA).

Electrospray-Ionization, Time-of-Flight Mass Spectrometry
Effluent from the cLC was directed into a QSTAR® Pulsar i quadrupole
orthogonal time-of-flight mass spectrometer through an IonSpray source (Applied
Biosystems). Mass spectra were collected every second for m/z 500 to 2500 from 5 to 55
min elution. Data collection and preliminary formatting were accomplished using
Analyst QS® software with BioAnalyst add-ons (Applied Biosystems). Specimens from
cases and controls were analyzed together in randomized order. This is described more
fully in Chapter 2, Part 3.

Peak Alignment
Because samples run on different days and columns can vary in elution time, 10
endogenous molecular species of average abundance that elute at approximately 2 minute
intervals throughout the chromatogram were determined (Table 2.2). This was detailed
in Chapter 2, Section 2.
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Evaluation of Candidate Molecular Species
Each species that appeared quantitatively different between groups was further
evaluated. To facilitate this, a second peak near the candidate peak (in both the
chromatographic and m/z dimension) but quantitatively comparable as determined by
visual inspection of a sampling of individual mass spectra in both groups was selected as
an internal control. This reference peak was then used to normalize the candidate peak of
interest, correcting for variability in specimen processing, specimen loading, ionization
efficiency and instrument performance and allowing comparison across runs performed
on different days. Thereafter, the molecular species were 'extracted' by the Analyst®
software to determine a quantitative peak height of both candidate and reference ions in
each specimen for all subjects.

Mass Spectral Data Analysis
The abundance (peak height) of each candidate and reference species was
tabulated as was the calculated ratio of each candidate species abundance relative to
reference species abundance within each patient. The log of that ratio was also
determined because abundance varied substantially. The data were submitted to
statistical analysis.

Selection of Reference Peaks for Chromatographic Normalization
Using 2-D and 3-D visualizations of complete serum runs, multiple peaks that
eluted at ~2 min intervals were selected as possible reference peaks. The Extract Ion
Chromatogram (XIC) function was used to check the chromatographic elution profile of a
small m/z range that included the m/z of the possible reference peaks. To be further
considered as possible reference peaks, chromatographic elution profiles of the selected
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peaks had to be relatively narrow (< 2 min), well shaped (close to Gaussian in shape), and
having elution profiles that were well resolved and distinguishable from those of other
molecular species of similar m/z. Those peaks that best met these criteria were further
investigated in serum runs from various individuals prepared and run on different days.
Ten peaks that eluted at ~2 min intervals and were ubiquitously present in all serum
samples were selected as markers.
Mass of Endogenous Time Reference (daltons)

Mean Elution Time (min)

1464.65

14.68

1439.52

17.01

2009.95

18.83

5062.28

21.34

546.31

23.54

545.33

26.12

1046.67

27.60

636.31

32.44

779.52

34.59

1619.07

36.88

Table 4.1. Mass and Elution Time of the Time Alignment Markers The mass and
typical elution time of the reference peaks used for time alignment are summarized in the
above table.

Statistical Analysis
Data are expressed as means + 1 standard error. Species that appeared to be
quantitatively different were considered. The twenty nine peaks reported here were those
that had p-values ≤ 0.05 upon further evaluation. Those species with the lowest p-values
are those that showed the best independent discrimination between case and control
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⎡⎛
⎞ ⎤
class = sign ⎢⎜⎜ ∑ ωi I i ⎟⎟ + c ⎥
⎢⎣⎝ i ∈Peaks ⎠ ⎥⎦
Equation 1. Equation used to determine case/control assignments using multiple peaks.
Sign is a function that returns +1 if the equation value is positive and -1 if the equation
value is negative. Class is a variable. +1 is returned if the sample is a case, and -1 if the
sample is a control. The intensities of each peak are multiplied by a weight and a
constant is added. We then look to see how well cases and controls are separated, with
the line drawn between them at 0.
samples and are reported in Table 4.4. All of the 29 ‘significant’ peaks were analyzed in
combination with each other for optimum discrimination between case and control peaks.
Combinations of as few as two peaks and as many as six peaks allowed for
discrimination between cases and controls with specificities ≥ 96% and sensitivities ≥
71%. Case/control determinations were determined using Equation 1 where ω is the
relative weight assigned to that peak within the combination, I is the XIC peak intensity
for a particular peak within each individual sample, and c is a constant for that
combination.

cLC-MS/MS Analysis
Candidate species demonstrating statistically different abundances between cases and
controls were further analyzed in an effort to chemically identify the candidate
molecules. A frozen specimen of supernatant (from the protein reduction step)
containing 0.5 μg of total protein was thawed and loaded onto the column and a MS run
was performed to determine the exact elution time of the peptide of interest. A MS/MS
run was performed on the same amount of protein with collection of Multi-Channel
Acquisition (MCA) fragmentation data at a set collision energy for the two min time span
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in which the peptide of interest eluted. MS/MS fragmentation data were produced at
several discrete collision energies, to produce fragmentation spectra that covered as much
of the total peptide sequence as possible. The spectrum were summed and visually
compared to exported data lists to insure that the software had assigned charge states
correctly. After any correction, the data list was transformed using the formula: +1 mass
= m/z value * charge – (charge – 1) so that all species had a +1 mass listed. The
corrected list was submitted to Mascot (www.matrixscience.com), a searchable MS
database allowing protein/peptide identification. The first peptide identified had a
monoisotopic mass of 2027.1 and was successfully identified as a fragment of inter-alpha
trypsin inhibitor heavy chain 4, and the second peptide had a monoisotopic mass of
1237.5 and was successfully identified as a fragment of fibrinogen B beta chain that was
amidated at the C-terminal end and had a pyroglutamic acid at the N-terminal end.

Results
Biomarker Characteristics
After time alignment, biomarker candidates were identified visually in an initial
process where multiple mass spectra were overlaid with cases and controls each assigned
a color. Those peaks that appeared to be predominantly one color were studied further.
The individual spectra were then submitted to peak height determination by the computer
equipped with Analyst® software (Applied Biosystems) which is the operating system for
the QqTOF mass spectrometer (Applied Biosystems). The XIC intensity of each of the
potential biomarkers was then tabulated. In addition a second peak that occurred in the
same time window which was not quantitatively different between cases and controls was
also selected. This represented an endogenous control for each peak under investigation,
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allowing for reduction of non-biologic variability. This was accomplished by dividing
the quantity of the candidate peak by the quantity of the endogenous control. The
Peak (m/z)

Mean Mass (daltons)

Mean Elution Time (min)

1.

718.8

4305.943 + 0.020

20.40 + 0.83

2.

719.2

4313.199 + 0.118

20.24 + 0.77

3.

734.8

1647.506 + 0.022

19.40 + 1.42

4.

649.3

648.322 + 0.037

24.27 + 0.67

5.

507.3

506.306 + 0.011

17.64 + 0.67

Table 4.2. Mass and elution times of 5 prospective biomarkers for PE
magnitude of this ratio for each specimen was recorded and statistical differences were
sought using a Student’s t-test comparing cases and controls.
While currently 29 molecular species have been found to be statistically different,
five of these were sufficiently different (p<0.0001) to suggest that they might allow for
excellent separation of the two groups without combination of any other peak. The
individual masses and elution times for the five PE biomarkers are summarized in Table
4.2.
The elution time (retention time) can also be expressed as a function of the
internal time controls. This is determined by the relative position of the peak of interest
between the time marker that runs precedes the biomarker and the time marker that
follows the peak of interest. This can be calculated as:
Rf = (elution time of biomarker – elution time of preceding time marker) /
(elution time of following time marker – elution time of preceding time marker)
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The Rf values are more reliable than the actual elution times. Elution times may
vary with new columns or with the altered performance of an existing column due to
fouling, but the Rf is not altered by these changes. The Rf values of the five biomarkers
are provided in Table 4.3.
Peak (m/z)

N

Rf Value Relative To Boundary Time Markers

1.

718.8

12

0.635 + 0.85

2.

719.2

12

0.737 + 0.072

3.

734.8

9

0.294 + 0.024

4.

649.3

10

0.343 + 0.120

5.

507.3

11

0.359 + 0.039

Table 4.3. The Rf Values for the PE Biomarkers Using the Internal Time Alignment
Peaks.

Reduction of Variability by Reference to an Endogenous Co-eluting
Control
One of the features of the current serum proteomic approach is the use of an
endogenous molecule that is found in all species and is not different between cases and
controls. Normalization of biomarker abundance to this internal control reduces nonbiological variation and improves the ability to utilize biomarkers in risk prediction.
Normalization involves mathematically dividing the abundance of the peak of interest by
the reference peak. The abundances are machine derived values. The abundance of a
given molecule represents the number of ions of a particular mass measured by the mass
spectrometer in a given mass spectrum or the sum of the number ions of a specific mass
observed in several mass spectra representing the full elution interval. Molecules
typically require 1.0 -1.5 min to move off the chromatographic column whereas mass
spectra are acquired every 1 second during that elution interval.
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The first two peaks with m/z 718.8 and 719.2 are in fact both significantly
different between cases and controls but the first is more abundant in cases and the
second is more abundant in controls. These two peaks are simply referenced to each
other, i.e. the abundance of the m/z 718.8 is divided by the abundance of the m/z 719.2.
For the other three peaks internal references were used. For the biomarker peak m/z
734.8, a coeluting reference peak at m/z 725.4 was chosen. For the biomarker m/z 649.3,
a coeluting reference peak at m/z 512.3 was chosen. For the biomarker m/z 507.3, a
coeluting reference at m/z 734.5 was chosen.
Using these ratios the mean value for the log ratios are as follows (Table 4.4):

Ratio

Mean Control

Mean PE

P value

1. log 718.8/719.2

-0.440 + 0.205

-0.0788 + 0.255

2 x 10-7

2. log 734.8/725.4

-0.278 + 0.225

-0.0215 + 0.123

0.000003

3. log 649.3/512.3

-0.098 + 0.386

+0.315 + 0.323

0.00003

4. log 507.3/734.5

+0.400 + 0.524

-0.0944 + 0.3962

0.0001

Table 4.4. Biomarker Abundance (after Normalization) in Cases and Controls

This method for normalization to internal controls was performed for all 29
potential biomarkers. These results are summarized in Table 4.5. The top 17 out of 29
peaks provided more powerful predictive capabilities when combined with other peaks.
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m/z

Ref Peak

charge

734.8
507.2
639.3
1026.4
942.5
649.3
634.3 L
1238.5
619.8
719.2
718.9
553.3
739.4
634.3 R
1074.4
509.3
505.3
718.9
757.2
571.3
585.3
541.3
601.3
676.7
785.3
756.4
805.3
593.3
783.3
568.8

742.8
734.5
582.3
518.3
559.2
512.3
582.3
623.4
623.4
725.4
725.4
518.3
518.3
582.3
518.3
649.4
649.4
719.2
734.8
565.3
579.3
512.3
512.3
685.2
512.3
758.5
559.2
572.3
559.2
565.3

2
1
1
2
1
2
1
1
2
6
6
1
2
1
2
2
2
6
3
1
1
2
2
3
1
1
1
1
1
4

Monoisotopic
mass
1468.6
507.2
639.3
2051.8
942.5
1297.6
634.3
1238.5
1238.6
4310.2
4308.4
553.3
1477.8
634.3
2147.8
1017.6
1009.6
4308.4
2269.6
571.3
585.3
1081.6
1201.6
2028.1
785.3
756.4
805.3
593.3
783.3
2272.2

p value

color

3.0E-06
1.5E-04
1.0E-05
1.0E-04
2.4E-02
3.0E-05
7.0E-04
3.2E-02
4.8E-02
1.0E-03
5.0E-02
1.0E-04
1.0E-04
2.0E-04
4.0E-04
1.0E-03
7.0E-03
2.0E-07
4.0E-03
8.0E-03
9.0E-03
1.1E-02
1.2E-02
1.9E-02
1.9E-02
2.0E-02
2.8E-02
3.9E-02
4.6E-02
5.0E-02

(white)
none
none
none
none
none
none
none
none
none
none
none

Table 4.5. Prospective Biomarkers Analyzed. A list of the 29 potential biomarker
peaks that were determined to be statistically significant (p-value ≤ 0.05). The top 18 of
these were used in combination with each other for the weighted discrimination analysis.

Use of the Biomarkers to Predict Women at Risk of a Later
Preeclampsia
One common measure of the predictive power of a biomarker is its sensitivity and
specificity. Sensitivity is a statistical term defined as the true positive rate or specifically
in this case the percentage of pregnant women who later develop PE that are correctly
identified by the biomarker. The specificity is defined as the true negative rate or in this

116

case the percentage of pregnant women with uncomplicated pregnancies correctly
identified. To use a biomarker for prediction in this manner a numeric threshold must be
established. To establish that numeric value, typically the range of values for the
biomarker are considered from lowest to highest and at each point the percent of subjects
correctly identified as positive and at that same point the percent of controls incorrectly
identified as positive. This is termed a receiver operator curve (ROC). Consistent with
general practice the false positive rate is limited to 20%. This is commonly considered
the maximum tolerated for a clinical test. The false positive rate (the percentage of
women with uncomplicated pregnancies, the control group, identified by the biomarker
as at risk for later PE) is calculated from the true negative rate being subtracted from
100%. Whatever the threshold is at a false positive rate of 20% or less (which is
equivalent to a specificity of 80% or higher) determines the threshold used to determine
whether someone is at risk or is not at risk. A threshold for each of the four ratios was
determined that allowed for the identification of subjects at risk of later PE. The
threshold for each was calculated such that there would be a specificity (a true negative
rate) of 80% or more. As stated, this is the same as a false positive rate no more than
20%. Using these mathematically determined thresholds the
Ratio

Threshold

Sensitivity

Specificity

1. log 718.8/719.2

> -0.301

82%

85%

2. log 734.8/725.4

> -0.11

71%

85%

3. log 649.3/512.3

> 0.253

67%

80%

4. log 507.3/734.5

< -0.125

48%

85%

Table 4.6 Sensitivity and Specificity of Each Biomarker (after Normalization)
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four ratios independently provided the following sensitivity (true positive) and specificity
(true negative) rates for single peptide biomarkers as summarized in Table 4.6.
If one combines the log 718.8/719.2 ratio (at a threshold of > -0.301) with the
ratio of log 649.3/512.3 now with a more stringent threshold of > 0.301, the sensitivity
improves to 89.3% with a specificity of 85%. Combination of the log 718.8/719.2 ratio
with log 734.8/725.5 with a threshold > -0.10 provides a sensitivity of 100% with a
specificity of 74%. Most of the potential biomarker peaks we determined to be
statistically significant do not result in high enough sensitivities or specificities when
considered as the sole discriminating factor between case and control sample sets. The
sensitivities and specificities were increased when multiple peaks were used in weighted
combinations. Various combinations of the peaks were analyzed. 17 of the peaks were
used in combination with as few as one and as many as five other peaks to provide a total
of 15 combinations that discriminated between the case and control groups with
specificities ≥ 96% and sensitivities ≥ 71%. (Table 4.7)

Biomarkers
1

2

3

4

5

Mass
Window
ω
Mass
Window
ω
Mass
Window
ω
m/z
Window
ω
m/z
Window

Const.

1

2

3

4

5

507.2
2
1
507.2
1
27
507.2
2
4
507.2
2
1
507.2
2

734.8
3
-16
619.8
3
1
734.8
3
-8
619.8
3
1
619.8
3

942.5
1
15
718.9
3
-32
739.4
6
1
734.8
3
-2
734.8
3

634.3 L
7
4
942.5
1
16
639.3
7
6
649.3
4
-2
942.5
1

639.3
7
1
649.3
4
-32

634.3L
7
31

505.3
5
1
649.3
4

1074.4
6
1
639.3
7
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6

4

Specificity

Sensitivity

Out of 23

Out of 24

100%
23/23
# wrong
96%
22/23
# wrong
100%
23/23
# wrong
96%
22/23
# wrong
96%
22/23

83%
20/24
4
88%
21/24
4
83%
20/24
4
88%
21/24
4
88%
21/24

6

7

8

9

10

11

12

13

14

15

16

17

18

ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω
m/z
Window
ω

2
507.2
2
3
718.9
3
-16
757.2
2
-1
507.2
2
4
507.2
2
2
507.2
2
1
734.8
3
-1
734.8
3
-5
734.8
3
-3
734.8
3
-4
1238.5
3
1
734.8
3
-2
734.8
3
-1

1
1238.5
3
2
719.2
3
8
719.2
3
1
719.2
3
2
1238.5
3
2
718.9
3
-1
1074.4
6
8
1026.4
6
33
1026.4
6
17
942.5
1
2
734.8
3
-16
942.5
1
1
1026.4
6
6

-4
734.8
3
-4
734.8
3
-16
942.5
1
17
734.8
3
-8
734.8
3
-4
942.5
1
2

1
649.3
4
-4
739.4
6
3
649.3
4
-1
649.3
4
-8
942.5
1
2
649.3
4
-2

639.3
7
2
639.3
7
1
1026.4
6
18
1026.4
6
64
1026.4
6
9
634.3R
7
1

12/12.1
3
-2

634.3R
7
3
639.3
7
3
634.3R
7
2

-4
509.3
5
1
634.3 L
7
1
634.3 L
7
4
509.3
5
1
505.3
5
1
553.3
6
5

2
553.3
6
2

639.3
7
4
634.3 L
7
1
1026.4
6
9

# wrong
100%
23/23
# wrong
100%
23/23
# wrong
100%
23/23
# wrong
96%
22/23
# wrong
100%
23/23
# wrong
96%
22/23
# wrong
100%
23/23
# wrong
96%
22/23
# wrong
87%
20/23
# wrong
96%
22/23
# wrong
96%
22/23
# wrong
96%
22/23
# wrong
91%
21/23
# wrong

4
83%
20/24
4
83%
20/24
4
83%
20/24
4
88%
21/24
4
83%
20/24
4
88%
21/24
4
71%
17/24
7
100%
24/24
1
100%
24/24
3
96%
23/24
2
96%
23/24
2
96%
23/24
2
96%
23/24
3

Table 4.7. Weighed Discrimination Analysis. Combinations of as few as two peaks
and as many as six peaks allowed for discrimination between cases and controls with
specificities ≥ 87% and sensitivities ≥ 71%. Case/control determinations were
determined using Equation 1 where ω is the relative weight assigned to that peak within
the combination, I is the XIC peak intensity for a particular peak within each individual
sample, and c is a constant for that combination. If class > 0 for a sample, that specimen
is assigned to the case set, whereas if class ≤ 0 for a sample, that specimen is assigned to
the control set.
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Discussion
We have applied the same proteomics approach as was described in Chapter 3 to
the analysis of sera collected from pregnant women at 12-14 weeks gestation. The cases
(n=23) went on to develop preeclampsia (typically occurring after 24 weeks gestation).
The controls (n=24) had normal, healthy pregnancies. Though these sera were collected
very early in the pregnancy, we have found 29 molecular species present at statistically
different levels between the case and control sample sets. The ratio between two
biomarker peptides very similar in both elution time and m/z successfully predict ~82%
of women who will later go on to develop PE more than 3 months prior to the onset of
symptoms (Figure 4.1, Figure 4.2). Using a several potential biomarkers in a combined

Figure 4.1. Peptide Biomarkers that predict ~82% of women who will go on to
develop preeclampsia. A sample overlay of the spectra of 8 women who went on
to develop PE (blue) and 8 women who had normal, healthy pregnancies.
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classification approach (Table 4.7) increases the sensitivity up to 100% and the
specificity up to 96% (Figure 4.3).

Figure 4.2. Classification of case/control patients using ratio of the relative
abundance of peak 718.8/719.2. These two peaks alone allowed for differentiation of
the two groups with a sensitivity of 82% and a specificity of 85%. This equates to a
misclassification of only 5 out of 28 case samples and 4 out of 27 control samples.
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B

Figure 4.3. Classification of case/control patients using a combination of different
peptide ratios. Using a combination of different peaks allowed for differentiation of the
samples into case/control groups with a maximum sensitivity up to 100% and a
maximum specificity up to 96%. This equates to a misclassification of 1 out of 23 case
samples and 0 out of 24 control samples. The markers used were 639.3, 718/719, 734.8,
and 1026.4.
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Two of the peptides identified as potential biomarkers for preeclampsia have
successfully been sequenced. The peak with m/z 676.7 was observed in its +3 charge
state and was identified as a fragment of the inter-alpha trypsin inhibitor heavy chain 4
with a polypeptide sequence of (qlglpgppdvpdhaayhpf). ITIH4 is an acute phase reactant
that also inhibits actin polymerization and phagocytosis of polymorphonuclear cells.
This class of peptides has been observed to increase in patients with inflammatory
disorders and may prove to be a mediator of infection or inflammatory response. (Pineiro
2004) The peak with m/z 691.8 was observed in its +2 state and was identified as
fibrinogen B beta chain that was amidated at the C-terminal end and had a pyroglutamic
acid at the N-terminal end. The polypeptide sequence of this species was (pyroegvndneegff-NH2). Fibrinogen is involved in blood clotting, fibrinolysis, cellular and
matrix responses, wound healing, the inflammatory response, and neoplasia. (Mosesson
2005) The reason for an increased amount of fibrinogen B beta chain we observed in
serum samples of women who developed preeclampsia is unknown, but we can surmise
that the peptide is not merely a cleavage fragment. The N-terminal end of this fragment
had a pyroglutamate and the C-terminal end was amidated. These modifications are
typically mediated by enzymes and suggest that this fragment was made by some cell for
a specific purpose.
Collectively, these data suggest strongly that the peptides described here have
great potential as useful biomarkers, identifying close to 100% of pregnant women who
will later develop preeclampsia. All of the peptides reported here had p-values ≤ 0.05,
however, the data suggest that these markers may become better predictors of PE in
combination with other markers rather than using individual markers for risk assessment.
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It is highly likely that additional biomarkers will be found that increase the sensitivity and
specificity of PE prediction. Further sequence identification of these potential
biomarkers may give insight to the pathology of this disease. This study was performed
using a relatively small sample set (n=55) and we recognize that these findings will need
to be confirmed in a larger number of samples. Additional samples can be studied to see
if the levels of these peptides change as delivery approaches. Women determined at high
risk for development of PE can be closely monitored and additional efforts can be made
to prevent onset of this disease.
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Chapter 5 – Concluding Remarks
Summary of Current Research Accomplishments
Sample Preparation
We developed a protein precipitation method that effectively removed the large,
highly-abundant proteins from serum. We showed that as the organic solvent used in the
precipitation protocol denatured the larger molecules, smaller molecules bound to larger
‘carrier proteins’ were released into the solution. We demonstrated both the
reproducibility of this method and the increased detection of smaller proteins and
peptides that were present in low amounts in serum. This method facilitated the search
for novel biomarkers for disease within the low-abundance, low-molecular weight serum
proteome.

Chromatographic Time Normalization
Due to the sensitivity of MS instrumentation, there is an inherent chromatographic
variability in the data from day-to-day and even run-to-run. To correct for this variation,
we developed a method to use 10 native serum peaks that were found in all samples as
internal controls. The 10 peaks selected eluted at approximate 2 minute intervals, and
were used as chromatographic reference points to normalize sample data run on different
days. Two-minute time windows centered on the elution time of a given marker were
overlayed for up to 16 different samples. Since all samples run were that of human
serum processed in the same manner, one would expect that the majority of the peptides
and proteins present in various serum samples would remain consistent. Without a
reliable method for chromatographic time alignment, samples did not appear to be
consistent. Using this method of internal standard alignment to overlay the samples, the
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consistency from sample to sample was greatly increased. This allowed for visual
inspection of these overlays for variations between the case and control sample sets. Any
peaks appearing to be quantitatively different can then be further analyzed to determine
their potential as biomarkers for the disease being investigated.

Sequencing of Intermediate to Large Peptides
The potential for discovery of biomarkers within the LMW fraction of the serum
proteome is great. Even after removal of the majority of protein from serum using
organic solvent precipitation, several thousand peaks were observable from a cLC-MS
run of just 0.5 µg of sample. After time alignment and analysis, peaks of interest were
selected and subjected to further analysis to determine quantitative differences between
case and control sets. Once these differences were determined, a protein or peptide was
ideally sequenced for optimum use as a potential biomarker. While it is possible to
adequately describe a unique peak using only m/z and relative elution time, it is
impossible to make any useful observations as to the possible role of a biomarker in the
pathology or progression of a disease without knowing the amino acid sequence of that
peptide. The method described here facilitated the identification of intermediate to large
serum peptides in their native, undigested form without the need for further sample
purification or processing. Even large, multiply charged peptides that were present in
relatively low quantities could potentially be sequenced using this method. As a
demonstration of the effectiveness of this method, a peptide with a m/z of 714.2 and a
charge state of +6 and a peptide with a m/z of 844.6 and a charge stated of +6 were
sequenced from a sample of serum. This method allowed for daughter ion fragment
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coverage of 33 of 39 of the amino acids for the peptide of m/z 714.2 and 42 out of 47
amino acids for the peptide with m/z of 844.6.

Biomarker Search for Preterm Birth
Serum samples of pregnant women were drawn at 22-24 weeks (visit 1) and 26-29
weeks (visit 3) gestational age. Some of these women went on to deliver their babies preterm (<37 weeks) and were considered the case subjects. The other women all went on to
deliver healthy, term babies and were considered to be the control set. The sample set
size analyzed was n=40 for each of the four sample categories (V1 case, V1 control, V3
case, V3 control) The methods outlined above were used to run the serum samples and
search the spectra for potential biomarkers. Potential biomarkers that were determined to
effectively discriminate between case and control samples (p-value < 0.05) were then
subjected to fragmentation in an effort to identify their protein sequence. For this sample
set, 3 peptide biomarkers were fully identified. A combination of these three biomarkers
predicted ~67% of women that went on to have a PTBup to 8 weeks prior to the actual
onset of preterm labor. A combination of these 3 biomarkers with 5 previously studied
candidate biomarkers provided a specificity of 89.8% and sensitivity of 81.0 %. Five
additional candidate serum markers were found at significantly altered levels, but have
not been successfully sequenced. Prevention is key to avoid PTB, and use of these novel
biomarkers for risk-assessment months in advance could have a positive effect on the
delay of preterm labor.

Biomarker Search for Preeclampsia
Serum samples of pregnant women were drawn at 12-14 weeks gestational age and
tracked through the end of their pregnancy. Some of these women (N=27) went on to
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have normal, healthy pregnancies, and the others (N=28) went on to develop
preeclampsia later on in their pregnancies. These sera were processed, run, and analyzed
as previously discussed. The spectra were then normalized, overlaid, and inspected for
the presence of potential serum biomarkers. A total of 29 unique molecular species were
found that were present at statistically significant levels between the case and control
sample sets. A ratio of two of the more promising peaks discriminated between the
groups with a p-value of 2.0 x 10-7 and successfully predicted ~82% of women having PE
more than 3 months prior to clinical symptoms. The discriminatory power of the 29
candidate biomarkers were tested in weighted combinations. The best of these weighted
combinations provided 96% sensitivity and 100% specificity more than 3 months prior to
clinical disease. Two of the 29 biomarkers have been fully identified using MS/MS.

Limitations of Current Research
Serum Protein Subset
In order to assure the release of LMW peptides from larger carrier proteins in
serum, and to assure reproducible protein depletion, two volumes of organic solvent were
added to one volume of raw serum. This caused almost all proteins > 5kDa to precipitate
out of the solution. This small subset of serum proteins has proven to show promise in
the search for novel serum biomarkers for disease, but we recognize that there are most
likely several potential serum markers > 5kDa in other molecular weight ranges that we
are not able to observe. Future efforts may attempt to characterize a different molecular
weight subset of the serum proteome.
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Sample Set Limitations
Samples for the PTB study were supplied by the MFMU network of the
NICHHD, collected as part a multi-center study. Having many research centers all over
the US contribute samples assured a good sampling of a wide demographic of women.
These samples were collected between 1992 and 1994. Long-term effects on the storage
of serum samples at -80ºC have not been thoroughly studied. All of these samples have
been stored under identical conditions so any variability introduced by storage is less
likely to affect studies comparing case and control from this set. Comparisons of these
samples to those that may have been collected more recently may prove to be less
reliable. Samples for the PE study were collected at local hospitals and so do not
represent as wide of a demographic as the PTB samples. Only enough serum for one
preparation (200 µl) was provided for the PE study. These samples had a much shorter
storage time than those for PTB, but small sample volumes limited how many runs can be
made to try and sequence peaks of interest.

Analysis of Data
A single MS run used 0.5 µg of total protein and eluted it over a 55 minute
gradient. The raw text data file for one sample can reach up to a gigabyte in size. The
large size of these files and the complexity of the data for samples of this type makes data
analysis very difficult. There are no software packages commercially available that can
adequately perform the alignment, normalization, deconvolution of charge states, and
comparison of the dozens (and potentially hundreds) of serum MS runs necessary in the
search for potential biomarkers. The current method for analysis (described in Chapter 2)
involved overlay of 8 case and 8 control spectra at a time and visually inspecting for
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differences in case and control samples that are further inspected as biomarker
candidates. This process is laborious and time-consuming, but has proven the most
reliable method for finding prospective biomarkers.

Future Research Objectives
Identification of Additional Biomarkers
For the PTB data set, there is still ~50% of the MS data yet to be analyzed. There
may be many more potential biomarkers identified from this yet unanalyzed portion of
the data. In addition, there are over 200 more samples from this same specimen set that
have been collected, but not analyzed at all. These samples could be used to search for
biomarkers, or as part of a study to validate the potential biomarkers singled out by the
initial set of 160 samples. The peptide sequence and protein identification has been
determined for only 3 biomarkers for the PTB set and 2 for the PE set. Many more
peptides have been selected and statistical analysis has shown that they can discriminate
between case and control samples with p-values of less than 0.05. To maximize the
utility of these molecular species as biomarkers for disease, the peptide sequence and
parent protein identity must be determined. Additionally, knowing which proteins these
biomarkers originate from may also give some clues to the pathology or progression of
the disease being studied.

Analysis of Additional Ob/Gyn-Related Diseases
In addition to analyzing more samples for PE and PTB to either validate markers
already identified or to search for additional potential biomarkers, we may seek to
analyze other obstetrically or gynecologically related diseases. Some examples of
potential diseases are recurrent miscarriage which affects ~5% of pregnancies, or
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endometriosis which affects ~10% of women in North America and is a leading cause of
infertility and hysterectomy in the US. The causes for these conditions are not well
understood, and currently there are not biomarkers to test for these conditions. To
complicate matters somewhat, surgery is currently required for a definitive diagnosis of
endometriosis. Serum biomarkers for the diagnosis of endometriosis would benefit many
women if they would not need surgery to reach that diagnosis.
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